id,pmid,doi,document_id,type,authors,title,isbn10,url,journal,volume,issue,dp_year,pages
3045,33058042.0,10.1007/s40265-020-01418-5,,JOURNAL ARTICLE,Al-Salama ZT,Imlifidase: first approval,,,Drugs,80,17,2020.0,1859-1864
627,,,EMEA/H/C/003995,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003995/WC500217100.pdf,,,,2016.0,
593,,,BLA:761034,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761034s000lbl.pdf,,,,2016.0,
3241,,,NDA:215310,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf,,,,2021.0,
165,,,BLA:103764,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/basnova032301LB.pdf,,,,2001.0,
3528,29302194.0,10.2147/JEP.S146034,,JOURNAL ARTICLE,"Jamil K, Pappas SC, Devarakonda KR",In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2,,,J Exp Pharmacol,10,,2018.0,1-7
3662,,,NDA:214373,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214373s000lbl.pdf,,,,2023.0,
567,1278093.0,,,JOURNAL ARTICLE,Taurog A,The mechanism of action of the thioureylene antithyroid drugs.,,,Endocrinology,98,4,1976.0,1031-46
87,12388666.0,10.1124/jpet.102.039867,,JOURNAL ARTICLE,,Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.,,,J Pharmacol Exp Ther,,,2002.0,
97,23393163.0,10.1124/mol.112.081935,,JOURNAL ARTICLE,,Vesnarinone suppresses TNFalpha mRNA expression by inhibiting valosin-containing protein,,,Mol Pharmacol,83,5,2013.0,
2751,32149769.0,10.1097/CM9.0000000000000797,,JOURNAL ARTICLE,"Fan HH, Wang LQ, Liu WL, An XP, Liu ZD, He XQ, Song LH, Tong YG",Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model,,,Chin Med J,,,2020.0,
3249,,,BLA:761177,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761177Orig1s000lbl.pdf,,,,2021.0,
2742,,,NDA:212273,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf,,,,2019.0,
44,20959606.0,10.1182/blood-2010-03-275305,,JOURNAL ARTICLE,,"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.",,,Blood,,,2011.0,
3679,,,EMEA/H/C/005122 review,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/assessment-report/omvoh-epar-public-assessment-report_en.pdf,,,,2023.0,
3263,,,000242929,DRUG LABEL,,,,https://www.pmda.go.jp/files/000242929.pdf,,,,2021.0,
2569,,,NDA:210795,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210795s000lbl.pdf,,,,2018.0,
3268,30806973.0,10.1007/s40265-019-01070-8,,JOURNAL ARTICLE,Deeks ED,Mirogabalin: first global approval,,,Drugs,79,4,2019.0,463-468
3670,,,NDA:216386,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216386s000lbl.pdf,,,,2023.0,
689,,,EMEA/H/C/004209,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004209/WC500232105.pdf,,,,2017.0,
259,,,NDA:020261,DRUG LABEL,,,,"http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020261s048,021192s021lbl.pdf",,,,2012.0,
380,21976485.0,10.1073/pnas.1105787108,,JOURNAL ARTICLE,"Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu PA",Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.,,,Proc. Natl. Acad. Sci. U.S.A.,108,46,2011.0,18843-8
469,,,BLA:125526,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125526Orig1s000Lbl.pdf,,,,2015.0,
598,,,EMEA/H/C/004059,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004059/WC500208434.pdf,,,,2016.0,
110,,,NDA:019810,DRUG LABEL,,,,"http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019810s098,022056s014lbl.pdf",,,,2014.0,
2527,,,NDA:210806,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf,,,,2018.0,
3683,,,NDA:215830,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf,,,,2023.0,
620,24113750.0,10.1124/mol.113.089482,,JOURNAL ARTICLE,"MacKenzie AE, Caltabiano G, Kent TC, Jenkins L, McCallum JE, Hudson BD, Nicklin SA, Fawcett L, Markwick R, Charlton SJ, Milligan G",The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35.,,,Mol. Pharmacol.,85,1,2014.0,91-104
2591,,,NDA:210557,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf,,,,2019.0,
217,,,BLA:125409,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125409s104lbl.pdf,,,,2015.0,
2717,,,NDA:211801,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf,,,,2019.0,
3062,29619657.0,10.1186/s13550-018-0378-4,,JOURNAL ARTICLE,"Sanchez-Crespo A, Jussing E, Björklund AC, Pokrovskaja Tamm K",Hallmarks in prostate cancer imaging with Ga68-PSMA-11-PET/CT with reference to detection limits and quantitative properties,,,EJNMMI Res,8,1,2018.0,27
187,,,BLA:125057,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s367lbl.pdf,,,,2014.0,
476,9405293.0,,,JOURNAL ARTICLE,"Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM",Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex.,,,Biochem. J.,329 ( Pt 1),,1998.0,191-6
8,22139434.0,10.1007/s00210-011-0713-z,,JOURNAL ARTICLE,,"Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.",,,Naunyn Schmiedebergs Arch Pharmacol,,,2012.0,
668,,,BLA:761052,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761052lbl.pdf,,,,2017.0,
3200,,,NDA:214018,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214018s000lbl.pdf,,,,2021.0,
115,24169554.0,10.1210/en.2013-1658,,JOURNAL ARTICLE,"Gingell JJ, Burns ER, Hay DL","Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.",,,Endocrinology,155,1,2014.0,21-6
3545,,,NDA:215814,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf,,,,2022.0,
2778,,,BLA:761119 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761119Orig1s000OtherR.pdf,,,,2020.0,
622,,,EMEA/H/C/000253,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000253/WC500040495.pdf,,,,2016.0,
545,7898101.0,,,JOURNAL ARTICLE,Rosenthal J,Nilvadipine: profile of a new calcium antagonist. An overview.,,,J. Cardiovasc. Pharmacol.,24 Suppl 2,,1994.0,S92-107
374,1469694.0,,,JOURNAL ARTICLE,"Hartman GD, Egbertson MS, Halczenko W, Laswell WL, Duggan ME, Smith RL, Naylor AM, Manno PD, Lynch RJ, Zhang G",Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.,,,J. Med. Chem.,35,24,1992.0,4640-2
3562,35199251.0,10.1208/s12248-022-00687-0,,JOURNAL ARTICLE,"Bocci G, Oprea TI, Benet LZ","State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References",,,AAPS J,24,2,2022.0,34
26,21985634.0,10.1111/j.1463-1326.2011.01517.x,,JOURNAL ARTICLE,,"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.",,,Diabetes Obes Metab,,,2012.0,
2313,,,NDA:761068,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761068s000lbl.pdf,,,,2018.0,
3224,,,NDA:213378,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf,,,,2021.0,
3208,,,BLA:761181,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761181s000lbl.pdf,,,,2021.0,
182,25120077.0,10.1038/npp.2014.207,,JOURNAL ARTICLE,"Hida H, Mouri A, Mori K, Matsumoto Y, Seki T, Taniguchi M, Yamada K, Iwamoto K, Ozaki N, Nabeshima T, Noda Y",Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC.,,,Neuropsychopharmacology,40,3,2015.0,601-13
647,,,PL 0458/0027,DRUG LABEL,,,,http://www.medicines.org.uk/emc/medicine/1073,,,,2017.0,
243,22080169.0,10.1007/s00280-011-1766-x,,JOURNAL ARTICLE,"Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, Zhang J, Dong M, Du X, Lu XP",Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.,,,Cancer Chemother. Pharmacol.,69,4,2012.0,901-9
2521,29670690.0,10.1021/acsmedchemlett.7b00421,,JOURNAL ARTICLE,"Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, Cianchetta G, Cai Z, Zhou D, Cui D, Chen P, Straley K, Tobin E, Wang F, David MD, Penard-Lacronique V, Quivoron C, Saada V, de Botton S, Gross S, Dang L, Yang H, Utley L, Chen Y, Kim H, Jin S, Gu Z, Yao G, Luo Z, Lv X, Fang C, Yan L, Olaharski A, Silverman L, Biller S, Su SM, Yen K.",Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers,,,ACS Med. Chem. Lett.,9,4,2018.0,300-5
522,,,NDA:020645,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020645s008lbl.pdf,,,,2011.0,
2748,8103915.0,10.1038/365160a0,,JOURNAL ARTICLE,"Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Sudhof TC, Niemann H, Jahn R",Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25,,,Nature,365,6442,1993.0,160-163
257,,,BLA:103795,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103795s5548lbl.pdf,,,,2015.0,
3188,23832378.0,10.1007/s00210-013-0901-0,,JOURNAL ARTICLE,"Fischer F, Vonderlin N, Zitron E, Seyler C, Scherer D, Becker R, Katus HA, Scholz EP",Inhibition of cardiac Kv1.5 and Kv4.3 potassium channels by the class Ia anti-arrhythmic ajmaline: mode of action,,,Naunyn Schmiedebergs Arch Pharmacol,386,11,2013.0,991-999
2594,,,NDA:212099,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf,,,,2019.0,
117,24558448.0,10.1371/journal.pone.0088910,,JOURNAL ARTICLE,,Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors,,,PLoS ONE,9,2,2014.0,e88910
377,21073468.0,10.1111/j.1471-4159.2010.07109.x,,JOURNAL ARTICLE,Miller GM,The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity.,,,J. Neurochem.,116,2,2011.0,164-76
3681,36380144.0,10.1007/s40265-022-01800-5,,JOURNAL ARTICLE,Keam SJ,Valemetostat tosilate: first approval,,,Drugs,82,16,2022.0,1621–1627
3706,,,BLA:761269,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s000lbl.pdf,,,,2023.0,
529,,,CP-2015-PI-01665-1,DRUG LABEL,,,,https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2015-PI-01665-1,,,,2015.0,
404,9205952.0,,,JOURNAL ARTICLE,"Alvarez-Guerra M, Alda O, Garay RP",Celiprolol: agonist and antagonist effects at cardiac beta 1- and vascular beta 2-adrenoceptors determined under in vivo conditions in the rat.,,,Naunyn Schmiedebergs Arch. Pharmacol.,355,6,1997.0,689-98
676,19297154.0,10.1016/j.bmcl.2009.02.111,,JOURNAL ARTICLE,"Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA, Probst GD, Song Y, Su T, Fan J, Wu Y, Li W, Woolfrey J, Sinha U, Wong PW, Edwards ST, Arfsten AE, Clizbe LA, Kanter J, Pandey A, Park G, Hutchaleelaha A, Lambing JL, Hollenbach SJ, Scarborough RM, Zhu BY","Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.",,,Bioorg. Med. Chem. Lett.,19,8,2009.0,2179-85
2923,,,BLA:761158,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf,,,,2020.0,
3678,,,EMEA/H/C/005122,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/omvoh-epar-product-information_en.pdf,,,,2023.0,
2734,,,BLA:761128,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf,,,,2019.0,
146,,,BLA:125277,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125277s071lbl.pdf,,,,2014.0,
456,22084396.0,10.1158/0008-5472.CAN-11-1515,,JOURNAL ARTICLE,"Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, Engst S, Johnston S, Friedman LS, Belvin M",Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.,,,Cancer Res.,72,1,2012.0,210-9
3252,,,EMEA/H/C/005316,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/assessment-report/bimzelx-epar-public-assessment-report_en.pdf,,,,2021.0,
3220,,,NDA:215014,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215014s000lbl.pdf,,,,2021.0,
462,,,NDA:021629,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021629s030lbl.pdf,,,,2015.0,
652,,,NDA:208854,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208854s000lbl.pdf,,,,2017.0,
447,18506437.0,10.1007/s00228-008-0478-6,,JOURNAL ARTICLE,"Sahasranaman S, Howard D, Roy S",Clinical pharmacology and pharmacogenetics of thiopurines.,,,Eur. J. Clin. Pharmacol.,64,8,2008.0,753-67
468,,10.1016/S0168-8278(14)61094-1,,JOURNAL ARTICLE,"N. Izumi, R. Tateishi, M. Seike, M. Kudo, H. Tamai, S. Kawazoe, K. Tanaka, M. Kurokawa, Y. Osaki, K. Yamamoto, M. Imawari","P933 ONCE-DAILY ORAL LUSUTROMBOPAG, ALTERNATIVE TO PLATELET TRANSFUSION IN THROMBOCYTOPENIC PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING RADIOFREQUENCY ABLATION: RESULTS FROM A PHASE 2B, RANDOMIZED, DOUBLE-BLIND STUDY",0168-8278 ,http://www.sciencedirect.com/science/article/pii/S0168827814610941,Journal of Hepatology,60,1,2014.0,S386
2590,31256368.0,10.1007/s40265-019-01161-6,,JOURNAL ARTICLE,Markham A,Alpelisib: First global approval,,,Drugs,79,11,2019.0,1249-53
386,21186796.0,10.1021/jm101016w,,JOURNAL ARTICLE,"Zhang Z, Wallace MB, Feng J, Stafford JA, Skene RJ, Shi L, Lee B, Aertgeerts K, Jennings A, Xu R, Kassel DB, Kaldor SW, Navre M, Webb DR, Gwaltney SL",Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.,,,J. Med. Chem.,54,2,2011.0,510-24
232,,,,BOOK,Laurence L. Brunton & Bruce A. Chabner & Bjorn C. Knollmann,Goodman and Gilman's The Pharmacological Basis of Therapeutics,0071624422,,,,,2011.0,
2705,,,BLA:761085,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761085s000lbl.pdf,,,,2019.0,
2108,27645238.0,,,JOURNAL ARTICLE,"Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, Tsai L, Bam RA, Stepan G, Stray KM, Niedziela-Majka A, Yant SR, Yu H, Kukolj G, Cihlar T, Lazerwith SE, White KL, Jin H","Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.",,,Antimicrob. Agents Chemother.,60,12,2016.0,7086-7097
335,26518.0,,,JOURNAL ARTICLE,"Galeone M, Moise G, Ferrante F, Cacioli D, Casula PL, Bignamini AA","Double-blind clinical comparison between a gastrin-receptor antagonist, proglumide, and a histamine H2-blocker, cimetidine.",,,Curr Med Res Opin,5,5,1978.0,376-82
9,20302302.0,10.1021/jm901893x,,JOURNAL ARTICLE,,"(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucito l (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.",,,J Med Chem,,,2010.0,
2004,,10.1016/S0016-5085(10)61017-7,,JOURNAL ARTICLE,"Gillberg, Per-Göran; Dahlström, Mikael; AU  - Starke, Ingemar; Östlund-Lindqvist, Ann-Margret",S1301 The IBAT Inhibition by A3309 - A Potential Mechanism for the Treatment of Constipation,,http://dx.doi.org/10.1016/S0016-5085(10)61017-7,Gastroenterology,138,5,2010.0,S-224
159,,,NDA:021938,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021938s027lbl.pdf,,,,2014.0,
2750,31132753.0,10.1016/j.phymed.2019.152956,,JOURNAL ARTICLE,Bailly C,"Cepharanthine: An update of its mode of action, pharmacological properties and medical applications",,,Phytomedicine,62,,2019.0,152956
2725,,,NDA:211970,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211970s000lbl.pdf,,,,2019.0,
3243,,,NDA:215206,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215206Orig1s000lbl.pdf,,,,2021.0,
289,,,NDA:206334,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206334s000lbl.pdf,,,,2014.0,
188,,,NDA:021081,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021081s062lbl.pdf,,,,2015.0,
2315,,,BLA:761077,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf,,,,2018.0,
2595,26137992.0,10.1038/srep12007,,JOURNAL ARTICLE,"Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Nykanen PS, Tormakangas OP, Palvimo JJ, Kallio PJ","Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies",,,Sci Rep,5,,2015.0,12007
3240,,,NDA:214916 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf,,,,2021.0,
3684,,,NDA:215830 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215830Orig1s000MultidisciplineR.pdf,,,,2023.0,
2701,,,NCT02215161,CLINICAL TRIAL,,Phase II single agent study of selinexor (KPT-330) in patients with metastatic castration-resistant prostate cancer (MCRPC) and prior therapy with abiraterone and/or enzalutamide,,https://clinicaltrials.gov/ProvidedDocs/61/NCT02215161/Prot_SAP_000.pdf,,,,2018.0,
103,10364735.0,10.1159/000029379,,JOURNAL ARTICLE,,"Reproterol: beta-2-agonist, theophylline, or both?",,,Respiration,66,3,1999.0,
597,11523024.0,,,JOURNAL ARTICLE,Karp JE,Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.,,,Semin. Hematol.,38,3 Suppl 7,2001.0,16-23
2901,30115648.0,10.1124/dmd.118.082966,,JOURNAL ARTICLE,"Lombardo F, Berellini G, Obach RS",Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds,,https://dmd.aspetjournals.org/content/dmd/46/11/1466.full.pdf,Drug Metab Dispos,46,11,2018.0,1466-1477
2714,18394554.0,10.1016/j.ccr.2008.02.009,,JOURNAL ARTICLE,"Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG","Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.",,,Cancer Cell,13,4,2008.0,311-320
610,,,EMEA/H/C/000872,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000872/WC500054377.pdf,,,,2015.0,
500,,,NDA:020212,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf,,,,2014.0,
325,,,NDA:021959,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf,,,,2010.0,
2944,,,NDA:213793 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf,,,,2020.0,
3265,33006602.0,10.1093/rheumatology/keaa605,,JOURNAL ARTICLE,"Nishida Y, Kano K, Nobuoka Y, Seo T",Sustained-release diclofenac conjugated to hyaluronate (diclofenac etalhyaluronate) for knee osteoarthritis: a randomized phase 2 study,,,Rheumatology,60,3,2020.0,1435-1444
3700,,,BLA:761339,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761339s000lbl.pdf,,,,2023.0,
1902,,,NDA:210251,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209360s000lbl.pdf,,,,2018.0,
3264,,,000242410,DRUG LABEL,,,,https://www.pmda.go.jp/files/000242410.pdf,,,,2021.0,
2721,31381333.0,10.1021/acs.jmedchem.9b00687,,JOURNAL ARTICLE,"Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, Zhang B, Wei M, Liu J, Luo L, Tang Z, Song H, Guo Y, Liu X, Su D, Zhang S, Song X, Zhou X, Hong Y, Chen S, Cheng Z, Young S, Wei Q, Wang H, Wang Q, Lv L, Wang F,Xu H, Sun H, Xing H, Li N, Zhang W, Wang Z, Liu G, Sun Z, Zhou D, Li W, Liu L, Wang L, Wang Z","Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase",,,J Med Chem,62,17,2019.0,7923-7940
124,10878285.0,,,JOURNAL ARTICLE,"Allison AC, Eugui EM",Mycophenolate mofetil and its mechanisms of action.,,,Immunopharmacology,47,2-3,2000.0,85-118
2760,,10.1101/2020.03.23.004580,,JOURNAL ARTICLE,"Li Z, Li X,  Huang YY, Wu Y, Zhou L, Liu R, Wu D, Zhang L, Liu H, Xu X, Zhang Y, Cui J, Wang X, Luo HB",FEP-based screening prompts drug repositioning against COVID-19,,,bioRxiv,,,2020.0,
2764,,,NDA:212608,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf,,,,2020.0,
3694,,,BLA:761309 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761309Orig1s000MultidisciplineR.pdf,,,,2023.0,
671,,,BLA:761037,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761037s000lbl.pdf,,,,2017.0,
2585,,,NDA:211230,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf,,,,2019.0,
129,24872026.0,10.1158/2326-6066.CIR-14-0040,,JOURNAL ARTICLE,"Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, Singh S, Wong S, Garner N, Leblanc H, Bunch RT, Blanset D, Selby MJ, Korman AJ","In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.",,,Cancer Immunol Res,2,9,2014.0,846-56
448,26171220.0,10.1002/prp2.136,,JOURNAL ARTICLE,"Jain MR, Giri SR, Trivedi C, Bhoi B, Rath A, Vanage G, Vyas P, Ranvir R, Patel PR","Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models.",,,Pharmacol Res Perspect,3,3,2015.0,e00136
2592,,,NDA:212306,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212306s000lbl.pdf,,,,2019.0,
276,20022913.0,10.1093/chemse/bjp092,,JOURNAL ARTICLE,"Meyerhof W, Batram C, Kuhn C, Brockhoff A, Chudoba E, Bufe B, Appendino G, Behrens M",The molecular receptive ranges of human TAS2R bitter taste receptors.,,,Chem. Senses,35,2,2010.0,157-70
562,,,NDA:050682,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf,,,,2012.0,
367,,,NDA:021022,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf,,,,2004.0,
2740,27412122.0,10.1007/s40265-016-0618-8,,JOURNAL ARTICLE,Markham A,Atezolizumab: First Global Approval,,,Drugs,76,12,2016.0,1227-1232
579,,,BLA:125249,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125249lbl.pdf,,,,2008.0,
793,,,NDA:208716,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf,,,,2017.0,
22,18447380.0,10.1021/jm800180e,,JOURNAL ARTICLE,,"Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.",,,J Med Chem,,,2008.0,
157,11755161.0,,,JOURNAL ARTICLE,"Noguchi H, Kitazumi K, Mori M, Shiba T","Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic.",,,Eur. J. Pharmacol.,434,1-2,2002.0,21-8
2732,24658078.0,10.1038/nm.3512,,JOURNAL ARTICLE,"Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, Davies MV, Alexander MJ, Devine M, Loveday KS, Underwood KW, Grinberg AV, Quisel JD, Chopra R, Pearsall RS, Seehra J, Kumar R",Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis,,,Nat Med,20,4,2014.0,408-414
3231,,,BLA:761178,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf,,,,2021.0,
3527,,,NDA:022231,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022231s000lbl.pdf,,,,2022.0,
2005,,,NDA:210491,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf,,,,2018.0,
132,,,NIHR HSC ID: 7234,ONLINE RESOURCE,,Zucapsaicin (Civamide) for episodic cluster headache,,http://www.hsc.nihr.ac.uk/files/downloads/2226/2524.a929981f.Zucapsaicin_Nov13.pdf,,,,2013.0,
189,,,EMEA/H/C/002548,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002548/WC500182307.pdf,,,,2015.0,
2915,17585216.0,10.1097/01.anes.0000267503.85085.c0,,JOURNAL ARTICLE,"Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, Wiard RP, Feldman PL, Collins H, Waszczak BL, Tilbrook GS",CNS 7056: a novel ultra-short-acting benzodiazepine,,,Anesthesiology,107,1,2007.0,60-66
3238,,,NDA:215383,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215383s000lbl.pdf,,,,2021.0,
75,10720420.0,10.1161/01.RES.86.5.580,,JOURNAL ARTICLE,,The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.,,,Circ Res,,,2000.0,
410,,,NDA:016419,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/016419s029lbl.pdf,,,,2008.0,
282,,,NDA:020637,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020637s026lbl.pdf,,,,2013.0,
61,8839659.0,10.1007/s002280050126,,JOURNAL ARTICLE,,Antimuscarinic effect of tiquizium bromide in vitro and in vivo.,,,Eur J Clin Pharmacol,,,1996.0,
2565,25531770.0,10.1371/journal.pone.0114686,,JOURNAL ARTICLE,"Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS","Characterization of structure and function of ZS-9, a K+ selective ion trap",,,PLoS ONE,9,12,2014.0,e114686
358,22805230.0,10.1097/WNF.0b013e31825a68c5,,JOURNAL ARTICLE,"Sedehizadeh S, Keogh M, Maddison P",The use of aminopyridines in neurological disorders.,,,Clin Neuropharmacol,35,4,,191-200
2771,,,NDA:209899,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf,,,,2020.0,
2731,,,BLA:761136,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761136lbl.pdf,,,,2019.0,
407,,,EMEA/H/C/000369,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000369/WC500053612.pdf,,,,2015.0,
3698,32976892.0,10.1016/j.neuropharm.2020.108333,,JOURNAL ARTICLE,"Althaus AL, Ackley MA, Belfort GM, Gee SM, Dai J, Nguyen DP, Kazdoba TM, Modgil A, Davies PA, Moss SJ, Salituro FG, Hoffmann E, Hammond RS, Robichaud AJ, Quirk MC, Doherty JJ","Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator",,,Neuropharmacology,181,,2020.0,108333
330,,,NDA:020563,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020563s124lbl.pdf,,,,2015.0,
341,,,BLA:125422,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125422s025lbl.pdf,,,,2014.0,
359,,,NDA:202799,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202799s001lbl.pdf,,,,2012.0,
3088,21118657.0,10.1503/jpn.100057,,JOURNAL ARTICLE,"Dean O, Giorlando F, Berk M",N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action,,,J Psychiatry Neurosci,36,2,2011.0,78-86
304,,,NDA:022393,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf,,,,2014.0,
396,15646370.0,,,JOURNAL ARTICLE,"Doi N, Hirotani C, Ukai K, Shimada O, Okuno T, Kurasaki S, Kiyofuji T, Ikegami R, Futamata M, Nakagawa T, Ase K, Chihara K","Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.",,,Arzneimittelforschung,54,12,2004.0,857-67
667,,,BLA:761069,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf,,,,2017.0,
2938,32668216.0,10.1016/j.celrep.2020.107940,,JOURNAL ARTICLE,"Pruijssers AJ, George AS, Schafer A, Leist SR, Gralinksi LE, Dinnon KH 3rd, Yount BL, Agostini ML, Stevens LJ, Chappell JD, Lu X, Hughes TM, Gully K, Martinez DR, Brown AJ, Graham RL, Perry JK, Du Pont V, Pitts J, Ma B, Babusis D, Murakami E, Feng JY, Bilello JP, Porter DP, Cihlar T, Baric RS, Denison MR, Sheahan TP",Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice,,,Cell Rep,32,3,2020.0,107940
1299,,,EMEA/H/C/004131,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004131/WC500239033.pdf,,,,2017.0,
2536,26144315.0,10.1016/j.ccell.2015.05.010,,JOURNAL ARTICLE,"Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, Timofeevski S, Katayama R, Dinh DM, Lam H, Lam JL, Yamazaki S, Hu W, Patel B, Bezwada D, Frias RL, Lifshits E, Mahmood S, Gainor JF, Affolter T, Lappin PB, Gukasyan H, Lee N, Deng S, Jain RK, Johnson TW, Shaw AT, Fantin VR, Smeal T.","PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.",,,Cancer Cell.,28,1,2015.0,70-81
2568,,,NDA:210303,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303Orig1s000lbl.pdf,,,,2018.0,
3196,29475723.0,10.1016/S1470-2045(18)30082-2,,JOURNAL ARTICLE,"Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O'Connor OA","Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study",,,Lancet Oncol,19,4,2018.0,486-496
2533,,,NDA:211651,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf,,,,2018.0,
505,,,NDA:020576,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020576s010lbl.pdf,,,,2010.0,
1197,,,NDA:208254,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdf,,,,2017.0,
2781,17332304.0,10.1158/1078-0432.CCR-06-1150,,JOURNAL ARTICLE,"Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E","Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor",,,Clin Cancer Res,13,5,2007.0,1576-1583
3554,,,EMEA/H/C/005680,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/lunsumio-epar-product-information_en.pdf,,,,2022.0,
644,,,NDA:208794,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208794s000lbl.pdf,,,,2017.0,
477,,,BLA:103909,DRUG LABEL,,,,http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/UCM200875.pdf,,,,2000.0,
149,,,NDA:021289,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021289s019lbl.pdf,,,,2014.0,
227,,,BLA:125320,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125320s170lbl.pdf,,,,2015.0,
455,16251241.0,,,JOURNAL ARTICLE,"Wikström B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, Ogasawara M, Kawashima Y, Ueno K, Mori A, Ueno Y","Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies.",,,J. Am. Soc. Nephrol.,16,12,2005.0,3742-7
269,20030735.0,10.1111/j.1472-8206.2009.00805.x,,JOURNAL ARTICLE,"Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bönisch H",Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline.,,,Fundam Clin Pharmacol,24,6,2010.0,729-39
249,,,NDA:022264,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022264s013s014lbl.pdf,,,,2014.0,
3401,,,BLA:761164,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761164s000lbl.pdf,,,,2022.0,
3665,,,NDA:216059 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216059Orig1s000MultidisciplineR.pdf,,,,2023.0,
2695,,,EMEA/H/C/004889,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/zynquista-epar-product-information_en.pdf,,,,2019.0,
197,,,BLA:125516,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125516s000lbl.pdf,,,,2015.0,
3080,,,NDA:213433 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213433Orig1s000MultidisciplineR.pdf,,,,2020.0,
161,20163176.0,10.1021/jm9015526,,JOURNAL ARTICLE,"McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ","Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.",,,J. Med. Chem.,53,6,2010.0,2443-63
663,,,NDA:208743,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf,,,,2017.0,
158,23279183.0,10.1111/gtc.12022,,JOURNAL ARTICLE,"Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, Akita K, Kirii Y",Activity-based kinase profiling of approved tyrosine kinase inhibitors.,,,Genes Cells,18,2,2013.0,110-22
3057,25387665.0,10.1007/s00011-014-0782-9,,JOURNAL ARTICLE,"Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M",Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo,,,Inflamm Res,64,1,2015.0,41-51
495,18305010.0,10.1124/jpet.108.136960,,JOURNAL ARTICLE,"Ehlert FJ, Griffin MT",Two-state models and the analysis of the allosteric effect of gallamine at the M2 muscarinic receptor.,,,J. Pharmacol. Exp. Ther.,325,3,2008.0,1039-60
3540,30917623.0,10.3390/molecules24061190,,JOURNAL ARTICLE,"Lee HT, Lee SH, Heo Y-S","Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology",,,Molecules,24,6,2019.0,1190
3689,,,BLA:761324,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324s000lbl.pdf,,,,2023.0,
369,,,NDA:017588,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017588s040lbl.pdf,,,,2014.0,
38,20845908.0,10.1021/jm100863x,,JOURNAL ARTICLE,,Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.,,,J Med Chem,,,2010.0,
264,,,BLA:125019,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125019s210s213lbl.pdf,,,,2013.0,
3556,,,EMEA/H/C/005442 review,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/assessment-report/yselty-epar-public-assessment-report_en.pdf,,,,2022.0,
3187,,,NDA:18603,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/18603s19lbl.pdf,,,,1998.0,
473,25271963.0,10.1021/jm500973a,,JOURNAL ARTICLE,"Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL",Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.,,,J. Med. Chem.,57,20,2014.0,8249-67
525,,,NDA:021749,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf,,,,2013.0,
3059,33320297.0,10.1007/s40265-020-01444-3,,JOURNAL ARTICLE,Markham A,Enarodustat: first approval,,,Drugs,,,2020.0,
657,,,NDA:208082,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf,,,,2017.0,
3225,,,NDA:214665,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf,,,,2021.0,
405,,,BLA:103979,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103979s5135lbl.pdf,,,,2010.0,
2769,,,NDA:211616,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf,,,,2020.0,
465,10991983.0,,,JOURNAL ARTICLE,"Herrick-Davis K, Grinde E, Teitler M",Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.,,,J. Pharmacol. Exp. Ther.,295,1,2000.0,226-32
3078,20605905.0,10.1124/jpet.110.168062,,JOURNAL ARTICLE,"Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K, Evans K, Sims GP, Pfarr DS, Bowen MA, Dall'Acqua W, Shlomchik M, Tedder TF, Kiener P, Jallal B, Wu H, Coyle AJ",B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody,,,J Pharmacol Exp Ther,335,1,2010.0,213-222
683,,,NDA:209195,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s000lbl.pdf,,,,2017.0,
415,1546145.0,,,JOURNAL ARTICLE,"Dingemanse J, Berlin I, Payan C, Thiede HM, Puech AJ",Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects.,,,Psychopharmacology (Berl.),106 Suppl,,1992.0,S68-70
312,,,NDA:021468,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021468s019lbl.pdf,,,,2014.0,
435,22686619.0,10.2165/11631090-000000000-00000,,JOURNAL ARTICLE,"Subramaniam JM, Whiteside G, McKeage K, Croxtall JC",Mogamulizumab: first global approval.,,,Drugs,72,9,2012.0,1293-8
3271,,,NDA:214985,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214985s000lbl.pdf,,,,2022.0,
57,22869577.0,10.1128/AAC.01186-12,,JOURNAL ARTICLE,,Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).,,,Antimicrob Agents Chemother,,,2012.0,
125,17915852.0,,,JOURNAL ARTICLE,"Binda C, Wang J, Pisani L, Caccia C, Carotti A, Salvati P, Edmondson DE, Mattevi A",Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs.,,,J. Med. Chem.,50,23,2007.0,5848-52
655,,,BLA:761053,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf,,,,2017.0,
3239,,,NDA:215383 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215383Orig1s000MultidisciplineR.pdf,,,,2021.0,
2930,,,BLA:761149 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761149Orig1s000PharmR.pdf,,,,2020.0,
2755,,10.1101/2020.04.03.023846,,JOURNAL ARTICLE,"Touret F, Gilles M, Barral K, Nougairede A, Decroly E, de Lamballerie X, Coutard B",In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication,,,bioRxiv,,,2020.0,
2535,,,NDA:210868 ,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf,,,,2018.0,
3077,,,NDA:213973 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213973Orig1s000MultidisciplineR.pdf,,,,2020.0,
2931,,,NDA:213433,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213433s000lbl.pdf,,,,2020.0,
513,8872297.0,,,JOURNAL ARTICLE,"Ziegler D, Haxhiu MA, Kaan EC, Papp JG, Ernsberger P","Pharmacology of moxonidine, an I1-imidazoline receptor agonist.",,,J. Cardiovasc. Pharmacol.,27 Suppl 3,,1996.0,S26-37
591,,,NDA:207318,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf,,,,2016.0,
1,,,,BOOK,Karen Baxter,Stockley's Drug Interactions,0853699143,,,,,2010.0,
172,,,NDA:206947,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf,,,,2015.0,
3557,,,EMEA/H/C/005638,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/sunlenca-epar-product-information_en.pdf,,,,2022.0,
190,,,NDA:022505,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022505s004lbl.pdf,,,,2013.0,
2584,,,NDA:211371,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211371Orig1s000MultidisciplineR.pdf,,,,2019.0,
587,,,BLA:103628,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103628s5258lbl.pdf,,,,2015.0,
305,,,NDA:017808,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017808s036lbl.pdf,,,,2015.0,
540,,,NDA:019481,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019481s013lbl.pdf,,,,2015.0,
397,,,NDA:019853,DRUG LABEL,,,,"http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19853s012,014lbl.pdf",,,,2004.0,
3415,35465163.0,10.1016/j.csbj.2022.03.030,,JOURNAL ARTICLE,"Cui WW, Wang SY, Zhang YQ, Wang Y, Fan YZ, Guo CR, Li XH, Lei YT, Wang WH, Yang XN, Hattori M, Li CZ, Wang J, Yu Y","P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough",,,Comput Struct Biotechnol J,20,,2022.0,1642-1653
36,22862294.0,10.1021/jm3009103,,JOURNAL ARTICLE,,"The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.",,,J Med Chem,,,2012.0,
461,,,NDA:207953,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207953s000lbl.pdf,,,,2015.0,
609,10776839.0,,,JOURNAL ARTICLE,"Dunn CJ, Goa KL",Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.,,,Drugs,59,3,2000.0,681-717
167,25414122.0,10.1007/s40265-014-0333-2,,JOURNAL ARTICLE,Garnock-Jones KP,Ripasudil: first global approval.,,,Drugs,74,18,2014.0,2211-5
365,,,NDA:204958,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204958lbl.pdf,,,,2015.0,
3236,,,NDA:215498,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215498s000lbl.pdf,,,,2021.0,
2558,,,BLA:761107,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761107s000lbl.pdf,,,,2018.0,
2903,,,NDA:213591,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf,,,,2020.0,
3207,,,NDA:211964 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf,,,,2021.0,
466,11855658.0,,,JOURNAL ARTICLE,Endoh M,Mechanism of action of Ca2+ sensitizers--update 2001.,,,Cardiovasc Drugs Ther,15,5,2001.0,397-403
138,21486038.0,10.1021/jm101459g,,JOURNAL ARTICLE,"Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A, Stensbøl TB","Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.",,,J. Med. Chem.,54,9,2011.0,3206-21
106,11830761.0,,,JOURNAL ARTICLE,Lapin I,Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug.,,,CNS Drug Rev,7,4,2001.0,471-81
630,20188549.0,10.1016/j.bmcl.2010.02.010,,JOURNAL ARTICLE,"Zhang YK, Plattner JJ, Akama T, Baker SJ, Hernandez VS, Sanders V, Freund Y, Kimura R, Bu W, Hold KM, Lu XS",Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application.,,,Bioorg. Med. Chem. Lett.,20,7,2010.0,2270-4
2736,27013195.0,10.1158/0008-5472.CAN-15-1313,,JOURNAL ARTICLE,"Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, Capo L, Verlinsky A, Leavitt M, Malik F, Avina H, Guevara CI, Dinh N, Karki S, Anand BS, Pereira DS, Joseph IB, Doñate F, Morrison K, Stover DR",Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models,,,Cancer Res,76,10,2016.0,3003-3013
618,23301156.0,10.1038/srep01035,,JOURNAL ARTICLE,"Realini N, Solorzano C, Pagliuca C, Pizzirani D, Armirotti A, Luciani R, Costi MP, Bandiera T, Piomelli D",Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity.,,,Sci Rep,3,,2013.0,1035
309,,,15300AMZ00256000,DRUG LABEL,,,,http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf,,,,2007.0,
391,24947465.0,10.1124/jpet.114.213793,,JOURNAL ARTICLE,"Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbøl TB, Kikuchi T",Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.,,,J. Pharmacol. Exp. Ther.,350,3,2014.0,589-604
25,19256507.0,10.1021/jm900210d,,JOURNAL ARTICLE,,"Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihy dro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.",,,J Med Chem,,,2009.0,
439,20093397.0,10.1124/jpet.109.160432,,JOURNAL ARTICLE,"Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Agai-Csongor E, Domány G, Tihanyi K, Adham N, Szombathelyi Z","Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.",,,J. Pharmacol. Exp. Ther.,333,1,2010.0,328-40
607,,,BLA:103949,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103949s5299lbl.pdf,,,,2015.0,
133,,,BLA:125514,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf,,,,2014.0,
3218,,,EUA:145802,DRUG LABEL,,,,https://www.fda.gov/media/145802/download,,,,2021.0,
56,18800822.0,10.1021/jm8001263,,JOURNAL ARTICLE,,4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.,,,J Med Chem,,,2008.0,
576,,,BLA:125521,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf,,,,2016.0,
2314,,,NDA:210493,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210493s000lbl.pdf/drugsatfda_docs/label/2014/125477s007lbl.pdf,,,,2018.0,
432,,,EMEA/H/C/004004,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004004/WC500192715.pdf,,,,2015.0,
193,,,NDA:020280,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020280s077lbl.pdf,,,,2014.0,
1700,21449606.0,10.1021/jm200049r,,JOURNAL ARTICLE,"Mascitti V, Maurer TS, Robinson RP, Bian J, Boustany-Kari CM, Brandt T, Collman BM, Kalgutkar AS, Klenotic MK, Leininger MT, Lowe A, Maguire RJ, Masterson VM, Miao Z, Mukaiyama E, Patel JD, Pettersen JC, Préville C, Samas B, She L, Sobol Z, Steppan CM, Stevens BD, Thuma BA, Tugnait M, Zeng D, Zhu T",Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.,,,J. Med. Chem.,54,8,2011.0,2952-60
650,,,NDA:209092,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf,,,,2017.0,
3189,,,EMEA/MRL/555/99-FINAL,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/mrl-report/albendazole-oxide-summary-report-2-committee-veterinary-medicinal-products_en.pdf,,,,1999.0,
2905,,,NDA:213246,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf,,,,2020.0,
55,20590641.0,10.1111/j.1476-5381.2010.00816.x,,JOURNAL ARTICLE,,Molecular determinants of state-dependent block of voltage-gated sodium channels by pilsicainide.,,,Br J Pharmacol,,,2010.0,
3666,,,NDA:217639,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s000correctedlbl.pdf,,,,2023.0,
474,,,NDA:208065,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf,,,,2015.0,
2758,32020029.0,10.1038/s41422-020-0282-0,,JOURNAL ARTICLE,"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G",Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro,,,Cell Res,30,3,2020.0,269-271
3054,31371478.0,10.1124/jpet.119.259341,,JOURNAL ARTICLE,"Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, Chikamatsu N, Hagihara C, Hashiba M, Iwanaga T","Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor",,,J Pharmacol Exp Ther,371,1,2019.0,162-170
3553,,,NDA:215515 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215515Orig1s000PharmR.pdf,,,,2022.0,
100,,,20800AMZ00077000,DRUG LABEL,,Coretec Injection 5 mg,,http://eisai.jp/medical/products/di/EPI/COR_A_EPI.pdf,,,,2009.0,
246,21466810.0,10.1016/j.lfs.2011.03.019,,JOURNAL ARTICLE,"Inayoshi A, Sugimoto Y, Funahashi J, Takahashi S, Matsubara M, Kusaka H","Mechanism underlying the block of human Cav3.2 T-type Ca2+ channels by benidipine, a dihydropyridine Ca2+ channel blocker.",,,Life Sci.,88,19-20,2011.0,898-907
543,2547493.0,,,JOURNAL ARTICLE,"Klöckner U, Isenberg G",The dihydropyridine niguldipine modulates calcium and potassium currents in vascular smooth muscle cells.,,,Br. J. Pharmacol.,97,3,1989.0,957-67
548,10533013.0,,,JOURNAL ARTICLE,"Wright RO, Lewander WJ, Woolf AD","Methemoglobinemia: etiology, pharmacology, and clinical management.",,,Ann Emerg Med,34,5,1999.0,646-56
2774,32141023.0,10.1007/s40265-020-01277-0,,JOURNAL ARTICLE,Duggan S,Osilodrostat: First Approval,,,Drugs,80,5,2020.0,495-500
634,22088449.0,,,JOURNAL ARTICLE,"Wang HP, Zhang L, Wang YX, Tan FL, Xia Y, Ren GJ, Hu P, Jiang J, Wang MZ, Xiao Y","Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.",,,Chin. Med. J.,124,13,2011.0,1933
3559,,,EMEA/H/C/005865,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_en.pdf,,,,2022.0,
3688,,,NDA:215887,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215887Orig1s000Correctedlbl.pdf,,,,2023.0,
226,,,BLA:125388,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf,,,,2014.0,
611,,,NDA:022081,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022081s033lbl.pdf,,,,2015.0,
564,,,NDA:020954,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf,,,,2015.0,
290,,,NDA:022011,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022011s013lbl.pdf,,,,2013.0,
3710,,,NDA:216974,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf,,,,2023.0,
171,15542782.0,,,JOURNAL ARTICLE,"Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL",Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.,,,Mol. Cancer Ther.,3,11,2004.0,1427-38
2418,,,NDA:210498,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf,,,,2018.0,
248,,,BLA:103705,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103705s5432lbl.pdf,,,,2014.0,
2542,24900436.0,10.1021/ml2002423,,JOURNAL ARTICLE,"Munchhof MJ, Li Q, Shavnya A, Borzillo GV, Boyden TL, Jones CS, LaGreca SD, Martinez-Alsina L, Patel N, Pelletier K, Reiter LA, Robbins MD, Tkalcevic GT","Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.",,,ACS Med. Chem. Lett.,3,2,2011.0,106-11
665,,,NDA:208772,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdf,,,,2017.0,
51,10428387.0,10.1016/S0968-0896(99)00003-6,,JOURNAL ARTICLE,,"Synthesis and antimuscarinic activity of a series of 4-(1-Imidazolyl)-2,2-diphenylbutyramides: discovery of potent and subtype-selective antimuscarinic agents.",,,Bioorg Med Chem,,,1999.0,
2557,28265006.0,10.1158/1535-7163,,JOURNAL ARTICLE,"Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al",Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.,,,Mol. Cancer Ther.,16,5,2017.0,861-870
2570,,,NDA:210922,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf,,,,2018.0,
288,9726653.0,,,JOURNAL ARTICLE,"Fujimoto S, Ohashi M, Hiramoto A, Inoue Y, Nagai K, Shiokawa H, Itoh T","Vasorelaxant effect of olprinone, an inhibitor of phosphodiesterase 3, on mesenteric small artery and vein of rabbits.",,,Eur. J. Pharmacol.,353,2-3,1998.0,239-46
6,19428599.0,10.1016/j.antiviral.2009.02.198,,JOURNAL ARTICLE,,T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.,,,Antiviral Res,,,2009.0,
509,17276408.0,,,JOURNAL ARTICLE,Triggle DJ,"Calcium channel antagonists: clinical uses--past, present and future.",,,Biochem. Pharmacol.,74,1,2007.0,1-9
403,,,BLA:125559,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125559Orig1s000lbl.pdf,,,,2015.0,
170,,,NDA:207103,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf,,,,2015.0,
3387,,,NDA:209607,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209607s000lbl.pdf,,,,2018.0,
3409,,,NDA:215866,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf,,,,2022.0,
1500,10385705.0,,,JOURNAL ARTICLE,"Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, Main MJ, Foord SM, Sexton PM",Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product.,,,Mol. Pharmacol.,56,1,1999.0,235-42
2913,,,NDA:213702,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf,,,,2020.0,
245,19010832.0,10.1158/1078-0432.CCR-08-0169,,JOURNAL ARTICLE,"Morris PG, Fornier MN",Microtubule active agents: beyond the taxane frontier.,,,Clin. Cancer Res.,14,22,2008.0,7167-72
656,,,BLA:761055,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf,,,,2017.0,
265,,,EMEA/H/C/000771,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf,,,,2014.0,
321,,,BLA:125151,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125151s0184lbl.pdf,,,,2013.0,
2600,31301033.0,10.1007/s40265-019-01168-z,,JOURNAL ARTICLE,"Paik J, Duggan S",Volanesorsen: First global approval,,,Drugs,79,12,2019.0,1349-54
83,22470110.0,10.1128/AAC.06283-11,,JOURNAL ARTICLE,,Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors.,,,Antimicrob Agents Chemother,,,2012.0,
560,,,NDA:203756,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf,,,,2012.0,
355,,,objectId=212,ONLINE RESOURCE,"Frank M. Dautzenberg, Dimitri E. Grigoriadis, Richard L. Hauger, Thomas Steckler, Wylie W. Vale.",Corticotropin-releasing factor receptors: CRF1 receptor. Last modified on 02/02/2015. Accessed on 19/06/2015. IUPHAR/BPS Guide to PHARMACOLOGY,,http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=212,,,,2015.0,
493,,,BLA:761035,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf,,,,2015.0,
258,,,BLA:103792,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103792s5311lbl.pdf,,,,2014.0,
180,,,NDA:200603,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603s015lbl.pdf,,,,2013.0,
527,,,mepronizine_ct_8952,DRUG LABEL,,,,http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-09/mepronizine_ct_8952.pdf,,,,2011.0,
2737,,,BLA:761139,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf,,,,2019.0,
2552,30298461.0,10.1007/s40265-018-0989-0,,JOURNAL ARTICLE,Duggan S,Caplacizumab: First Global Approval.,,,Drugs,78,15,2018.0,1639-42
2728,,,NDA:211765,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf,,,,2019.0,
34,19263460.0,10.1002/cmdc.200900014,,JOURNAL ARTICLE,,"Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.",,,ChemMedChem,,,2009.0,
306,,,NDA:021999,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021999s029lbl.pdf,,,,2014.0,
3258,,,EMEA/H/C/005475,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/voxzogo-epar-product-information_en.pdf,,,,2021.0,
4,19661462.0,10.1161/CIRCRESAHA.109.198572,,JOURNAL ARTICLE,,Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity.,,,Circ Res,,,2009.0,
84,24102143.0,10.1111/bph.12408,,JOURNAL ARTICLE,,Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.,,,Br J Pharmacol,,,2014.0,
617,,,NDA:208524,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208524s000lbl.pdf,,,,2016.0,
483,,,BLA:125547,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf,,,,2015.0,
612,9875499.0,,,JOURNAL ARTICLE,"Lee JH, Lee JM, Kim JK, Ahn SK, Lee SJ, Kim MY, Jew SS, Park JG, Hong CI","Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.",,,Arch. Pharm. Res.,21,5,1998.0,581-90
3414,35347635.0,10.1007/s40265-022-01700-8,,JOURNAL ARTICLE,Markham A,Gefapixant: first approval,,,Drugs,82,6,2022.0,691-695
239,18974361.0,10.1124/jpet.108.145672,,JOURNAL ARTICLE,"Perez-Reyes E, Van Deusen AL, Vitko I","Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs.",,,J. Pharmacol. Exp. Ther.,328,2,2009.0,621-7
3686,26191358.0,10.1021/acsmedchemlett.5b00117,,JOURNAL ARTICLE,"Hoveyda HR, Fraser GL, Dutheuil G, El Bousmaqui M, Korac J, Lenoir F, Lapin A, Noel S",Optimization of novel antagonists to the neurokinin-3 receptor for the treatment of sex-hormone disorders (part II),,,ACS Med Chem Lett,6,7,2015.0,736-740
3056,33062187.0,10.1021/acsmedchemlett.0c00176,,JOURNAL ARTICLE,"Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T","Discovery of dotinurad (FYU-981), a new phenol derivative with highly potent uric acid lowering activity",,,ACS Med Chem Lett,11,10,2020.0,2017-2023
2909,31085175.0,10.1016/j.ccell.2019.04.006,,JOURNAL ARTICLE,"Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, Patt WC, Ruiz-Soto R, Su Y, Telikepalli H, Town A, Turner BA, Vogeti L, Vogeti S, Yates K, Janku F, Abdul Razak AR, Rosen O, Heinrich MC, Flynn DL",Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants,,,Cancer Cell,35,5,2019.0,738-751
3388,,,EMEA/H/C/005676,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/xevudy-epar-product-information_en.pdf,,,,2021.0,
602,7693433.0,,,JOURNAL ARTICLE,"Goa KL, Brogden RN","Propiram. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use as an analgesic.",,,Drugs,46,3,1993.0,428-45
14,20863829.0,10.1016/j.ejphar.2010.09.019,,JOURNAL ARTICLE,,"Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.",,,Eur J Pharmacol,,,2010.0,
160,21575866.0,10.1016/j.ccr.2011.04.004,,JOURNAL ARTICLE,"Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, Oikawa N, Tsukuda T, Ishii N, Aoki Y","CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.",,,Cancer Cell,19,5,2011.0,679-90
346,24995399.0,10.1111/cbdd.12390,,JOURNAL ARTICLE,"Song W, Zhang X, Li S, Xu W","Design, synthesis, and preliminary activity evaluation of novel pyrimidine derivatives as acid pump antagonists.",,,Chem Biol Drug Des,85,3,2015.0,306-14
3259,,,NDA:022454,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022454Orig1s000Lbl.pdf,,,,2021.0,
2761,,10.1101/2020.02.05.935387,,JOURNAL ARTICLE,"Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, Zhang H",Teicoplanin potently blocks the cell entry of 2019-nCoV,,,bioRxiv,,,2020.0,
121,21709094.0,10.1128/AAC.00833-10,,JOURNAL ARTICLE,,"In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions",,,Antimicrob. Agents Chemother.,55,9,2011.0,4394-7
463,1387020.0,,,JOURNAL ARTICLE,"Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T","Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.",,,Br. J. Pharmacol.,105,4,1992.0,787-91
569,23755755.0,,,JOURNAL ARTICLE,"Maenthaisong R, Tacconelli S, Sritara P, Del Boccio P, Di Francesco L, Sacchetta P, Archararit N, Aryurachai K, Patrignani P, Suthisisang C",Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.,,,Int J Immunopathol Pharmacol,26,2,,403-17
2898,15546675.0,10.1016/j.yrtph.2004.08.004,,JOURNAL ARTICLE,"Contrera JF, Matthews EJ, Kruhlak NL, Benz RD",Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose,,https://www.sciencedirect.com/science/article/abs/pii/S0273230004001138,Regul Toxicol Pharmacol,40,3,2004.0,185-206
475,15123680.0,,,JOURNAL ARTICLE,"Fu T, Mukhopadhyay D, Davidson NO, Borensztajn J",The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.,,,J. Biol. Chem.,279,27,2004.0,28662-9
491,19582593.0,10.1007/s12013-009-9057-4,,JOURNAL ARTICLE,"Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, Kraus RL, Santarelli VP, Li Y, Barrow JC, Yang ZQ, Schlegel KA, Rittle KE, Reger TS, Bednar RA, Lemaire W, Mullen FA, Ballard JE, Tang C, Dai G, McManus OB, Koblan KS, Renger JJ",Positive allosteric interaction of structurally diverse T-type calcium channel antagonists.,,,Cell Biochem. Biophys.,55,2,2009.0,81-93
3198,,,NDA:214200 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214200Orig1s000PharmR.pdf,,,,2021.0,
3204,,,NDA:214231,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf,,,,2021.0,
2729,,,BLA:761062,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf,,,,2019.0,
2719,20855361.0,10.1177/0333102410370873,,JOURNAL ARTICLE,"Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, Xu YC",Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan,,,Cephalalgia,30,10,2010.0,1159-1169
2700,19654408.0,10.1182/blood-2009-05-222034,,JOURNAL ARTICLE,"Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS",AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML),,,Blood,114,14,2009.0,2984-92
199,,,BLA:125370,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125370s053lbl.pdf,,,,2014.0,
3073,,,BLA:761171,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf,,,,2020.0,
578,,,BLA:761033,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf,,,,2016.0,
45,23601816.0,10.1016/j.bmc.2013.02.058,,JOURNAL ARTICLE,,Synthesis and biological evaluation of Esaprazole analogues showing sigma1 binding and neuroprotective properties in vitro.,,,Bioorg Med Chem,,,2013.0,
2897,21818695.0,10.1208/s12248-011-9290-9,,JOURNAL ARTICLE,"Benet LZ, Broccatelli F, Oprea TI",BDDCS applied to over 900 drugs,,https://link.springer.com/content/pdf/10.1208/s12248-011-9290-9.pdf,The AAPS journal,13,4,2011.0,519-547
3413,33613288.0,10.3389/fphar.2020.628956,,JOURNAL ARTICLE,"Roux  S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, Clozel JP, Clozel M","Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm",,,J Pharmacol Exp Ther,283,3,1997.0,1110-1118
150,,,NDA:021322,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21322lbl.pdf,,,,2004.0,
1400,14623894.0,,,JOURNAL ARTICLE,"Pham V, Wade JD, Purdue BW, Sexton PM",Spatial proximity between a photolabile residue in position 19 of salmon calcitonin and the amino terminus of the human calcitonin receptor.,,,J. Biol. Chem.,279,8,2004.0,6720-9
356,21482695.0,10.1158/1535-7163.MCT-10-0792,,JOURNAL ARTICLE,"Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F, Clackson T","Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.",,,Mol. Cancer Ther.,10,6,2011.0,1059-71
3199,,,NDA:213026,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213026lbl.pdf,,,,2021.0,
111,9520489.0,,,JOURNAL ARTICLE,"Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF",Calcimimetics with potent and selective activity on the parathyroid calcium receptor.,,,Proc. Natl. Acad. Sci. U.S.A.,95,7,1998.0,4040-5
281,8862723.0,,,JOURNAL ARTICLE,"Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M",Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.,,,Anticancer Drugs,7,5,1996.0,548-57
164,18672868.0,10.1021/jm800355c,,JOURNAL ARTICLE,"Pinto-Bazurco Mendieta MA, Negri M, Jagusch C, Müller-Vieira U, Lauterbach T, Hartmann RW","Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.",,,J. Med. Chem.,51,16,2008.0,5009-18
338,17300164.0,,,JOURNAL ARTICLE,"Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, Aubin Y, Bateman KP, Chauret N, Day SH, Lévesque JF, Seto C, Silva JH, Trimble LA, Carriere MC, Denis D, Greig G, Kargman S, Lamontagne S, Mathieu MC, Sawyer N, Slipetz D, Abraham WM, Jones T, McAuliffe M, Piechuta H, Nicoll-Griffith DA, Wang Z, Zamboni R, Young RN, Metters KM","Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).",,,J. Med. Chem.,50,4,2007.0,794-806
3074,,,BLA:761171 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761171Orig1s000MultidisciplineR.pdf,,,,2020.0,
2883,27926532.0,10.18632/oncotarget.13749,,JOURNAL ARTICLE,"He JX, Wang M, Huan XJ, Chen CH, Song SS, Wang YQ, Liao XM, Tan C, He Q, Tong LJ, Wang YT, Li XH, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Gao ZW, Chen XY, Xiong B, Lu XL, Ding J, Yang CH, Miao ZH","Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution",,,Oncotarget,8,3,2017.0,4156–4168
3392,,,NDA:216196,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216196s000lbl.pdf,,,,2022.0,
35,11256231.0,10.1358/mf.2000.22.8.701373,,JOURNAL ARTICLE,,Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.,,,Methods Find Exp Clin Pharmacol,,,2000.0,
3416,,,EMEA/H/C/005973,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf,,,,2022.0,
2900,24306326.0,10.1007/s11095-013-1222-1,,JOURNAL ARTICLE,"Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H",Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches,,https://link.springer.com/content/pdf/10.1007/s11095-013-1222-1.pdf,Pharm Res,31,4,2014.0,1002-1014
3539,,,BLA:761289,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761289Orig1s000Correctedlbl.pdf,,,,2022.0,
17,21502615.0,10.1128/AAC.01565-10,,JOURNAL ARTICLE,,"In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.",,,Antimicrob Agents Chemother,,,2011.0,
345,,10.1002/jlcr.1116,,JOURNAL ARTICLE,"Shin, Hyun-Il; Lee, Juyoung; Kim, Dae-Kee","Synthesis of 5-​ethyl-​2-​{5-​[4-​(2-​hydroxyethyl)​piperazin-​1-​ylsulfonyl]​-​2-​n-​propoxyphenyl}​-​7-​n-​propyl-​3,​5-​dihydro-​4H-​pyrrolo[3,​2-​d]​-​[2-​14C]​pyrimidin-​4-​one.2 HCl (14C-​SK3530.2 HCl)",,,J Labelled Comp Radiopharm.,49,13,2006.0,1141–1149
2722,,,NDA:212194,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0212194s000lbl.pdf,,,,2019.0,
592,24847974.0,10.1021/jm500475k,,JOURNAL ARTICLE,"Lanier M, Ambrus G, Cole DC, Davenport R, Ellery J, Fosbeary R, Jennings AJ, Kadotani A, Kamada Y, Kamran R, Matsumoto S, Mizukami A, Okubo S, Okada K, Saikatendu K, Walsh L, Wu H, Hixon MS",A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT).,,,J. Med. Chem.,57,12,2014.0,5459-63
142,11716850.0,,,JOURNAL ARTICLE,"Sunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, Seino S","The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.",,,Eur. J. Pharmacol.,431,1,2001.0,119-25
2907,,,NDA:213246 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213246Orig1s000MultidisciplineR.pdf,,,,2020.0,
555,,,NDA:021160,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21160lbl.pdf,,,,2001.0,
2724,27378309.0,10.1111/bjh.14214,,JOURNAL ARTICLE,"Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, Silva-Garcia A, Zhou C, Hutchaleelaha A, Patskovska L, Patskovsky Y, Almo SC, Sinha U, Metcalf BW, Archer DR","GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease",,,Br J Haematol,175,1,2016.0,141-153
673,21570283.0,10.1016/j.bmcl.2011.04.029,,JOURNAL ARTICLE,"Kim HJ, Kwak WY, Min JP, Lee JY, Yoon TH, Kim HD, Shin CY, Kim MK, Choi SH, Kim HS, Yang EK, Cheong YH, Chae YN, Park KJ, Jang JM, Choi SJ, Son MH, Kim SH, Yoo M, Lee BJ","Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.",,,Bioorg. Med. Chem. Lett.,21,12,2011.0,3809-12
317,,,NDA:203284,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203284s001lbl.pdf,,,,2014.0,
3052,32361823.0,10.1007/s40265-020-01317-9,,JOURNAL ARTICLE,Markham A,Tepotinib: first approval,,,Drugs,80,8,2020.0,829-833
114,,,BLA:125477,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125477s007lbl.pdf,,,,2014.0,
3667,,,NDA:217639 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217639Orig1s000MultidisciplineR.pdf,,,,2023.0,
3050,28928122.0,10.1124/jpet.117.242503,,JOURNAL ARTICLE,"Ariazi JL, Duffy KJ, Adams DF, Fitch DM, Luo L, Pappalardi M, Biju M, DiFilippo EH, Shaw T, Wiggall K, Erickson-Miller C","Discovery and preclinical characterization of GSK1278863 (daprodustat), a small molecule hypoxia inducible factor-prolyl hydroxylase inhibitor for anemia",,,J Pharmacol Exp Ther,363,3,2017.0,336-347
315,,,NDA:017563,DRUG LABEL,,,,"http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017563s023,020222s005lbl.pdf",,,,2014.0,
3682,37407698.0,10.1038/s42003-023-05071-y,,JOURNAL ARTICLE,"Lin M, Zeng X, Duan Y, Yang Z, Ma Y, Yang H, Yang X, Liu X",Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants,,,Commun Biol,6,1,2023.0,694-700
2754,,10.1101/2020.03.20.999730,,JOURNAL ARTICLE,"Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S",Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,,,bioRxiv,,,2020.0,
3707,,,BLA:761269 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761269Orig1s000PharmR.pdf,,,,2023.0,
3663,,,NDA:214373 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214373Orig1s000IntegratedR.pdf,,,,2023.0,
2575,,,BLA:761092,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761092s000lbl.pdf,,,,2018.0,
3253,,,EMEA/H/C/005316 review,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf,,,,2021.0,
464,9469684.0,,,JOURNAL ARTICLE,"Brown LA, Levin GM","Sertindole, a new atypical antipsychotic for the treatment of schizophrenia.",,,Pharmacotherapy,18,1,,69-83
460,,,NDA:021882,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021882s021lbl.pdf,,,,2015.0,
10,22889351.0,10.1021/jm300884k,,JOURNAL ARTICLE,,"Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.",,,J Med Chem,,,2012.0,
2530,30506139.0,10.1007/s40265-018-1028-x,,JOURNAL ARTICLE,Shirley M,Dacomitinib: First Global Approval.,,,Drugs,78,18,2018.0,1947-53
21,23742252.0,10.1021/jm400402q,,JOURNAL ARTICLE,,"Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.",,,J Med Chem,,,2013.0,
2715,,,NDA:210828,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210828s000lbl.pdf,,,,2019.0,
2416,,,NDA:210238,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf,,,,2018.0,
211,2419701.0,,,JOURNAL ARTICLE,"Holck M, Fischli W, Hefti F, Gerold M","Cardiovascular effects of the new angiotensin-converting-enzyme inhibitor, cilazapril, in anesthetized and conscious dogs.",,,J. Cardiovasc. Pharmacol.,8,1,1986.0,99-108
2549,,,NDA:761090,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf,,,,2018.0,
3232,,,NDA:215341,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf,,,,2021.0,
3382,,,EMEA/H/C/005854,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/regkirona-epar-product-information_en.pdf,,,,2021.0,
2730,,,BLA:761125,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf,,,,2019.0,
690,24170767.0,10.1158/1535-7163.MCT-12-0993-T,,JOURNAL ARTICLE,"Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA, Fracasso PR, Wilkie DP, Hentemann M, Wilhelm SM, Scott WJ, Mumberg D, Ziegelbauer K",BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.,,,Mol. Cancer Ther.,12,11,2013.0,2319-30
41,9559824.0,,,JOURNAL ARTICLE,,"In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent.",,,Antimicrob Agents Chemother,,,1998.0,
2554,,,BLA:761089 ,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761089s000lbl.pdf,,,,2018.0,
349,8536820.0,,,JOURNAL ARTICLE,"Göke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, Kleist P, Arnold R, Lücker PW",Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve.,,,Digestion,56,6,1995.0,493-501
195,12482421.0,,,JOURNAL ARTICLE,"Ohwada J, Tsukazaki M, Hayase T, Oikawa N, Isshiki Y, Fukuda H, Mizuguchi E, Sakaitani M, Shiratori Y, Yamazaki T, Ichihara S, Umeda I, Shimma N","Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole.",,,Bioorg. Med. Chem. Lett.,13,2,2003.0,191-6
300,23940628.0,10.1371/journal.pone.0070690,,JOURNAL ARTICLE,"Barrière DA, Mallet C, Blomgren A, Simonsen C, Daulhac L, Libert F, Chapuy E, Etienne M, Högestätt ED, Zygmunt PM, Eschalier A",Fatty acid amide hydrolase-dependent generation of antinociceptive drug metabolites acting on TRPV1 in the brain.,,,PLoS ONE,8,8,2013.0,e70690
66,12510841.0,10.1007/BF02977007,,JOURNAL ARTICLE,,"Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159.",,,Arch Pharm Res,,,2002.0,
488,13757612.0,,,JOURNAL ARTICLE,"KOHOUT J, KORBOVA L, BLAZEK K",[Effect of anthistaminic drugs on the appearance of experimental gastric ulcer. III. Effect of mephenhydramine (alphadril) and polydroxyethylenesorbitanmonooleate on the appearance of gastric ulcers in guinea pigs].,,,Cas. Lek. Cesk.,100,,1961.0,905-9
487,13499132.0,,,JOURNAL ARTICLE,LENKE D,[Pharmacological effects of phathalazine and phthalazone derivatives. I].,,,Arzneimittelforschung,7,11,1957.0,678-81
54,22264484.0,10.1016/j.bmcl.2011.12.116,,JOURNAL ARTICLE,,Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists.,,,Bioorg Med Chem Lett,,,2012.0,
645,11314603.0,,,JOURNAL ARTICLE,"Nagatomo T, Hosohata Y, Ohnuki T, Nakamura T, Hattori K, Suzuki J, Ishiguro M",Bopindolol: pharmacological basis and clinical implications.,,,Cardiovasc Drug Rev,19,1,2001.0,9-24
502,,,NDA:020766,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020766s035lbl.pdf,,,,2015.0,
401,22633824.0,10.1016/S0140-6736(12)60771-5,,JOURNAL ARTICLE,"Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R","Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.",,,Lancet,380,9836,2012.0,29-36
3046,,,EMEA/H/C/005113,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf,,,,2020.0,
16,25043012.0,10.1038/nature13527,,JOURNAL ARTICLE,,Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.,,,Nature,,,2014.0,
3235,,,NDA:214783,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214783s000lbl.pdf,,,,2021.0,
237,,,BLA:125156,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125156s106lbl.pdf,,,,2015.0,
2928,,,BLA:212154 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212154Orig1s000PharmR.pdf,,,,2020.0,
666,27780853.0,10.1158/1078-0432.CCR-16-0569,,JOURNAL ARTICLE,"Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, Ning Y, Wardwell SD, Miller D, Song Y, Eichinger L, Moran L, Huang WS, Liu S, Zou D, Wang Y, Mohemmad Q, Jang HG, Ye E, Narasimhan N, Wang F, Miret J, Zhu X, Clackson T, Dalgarno D, Shakespeare WC, Rivera VM",The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.,,,Clin. Cancer Res.,22,22,2016.0,5527-5538
1298,,,NDA:210259,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf,,,,2017.0,
90,23859232.0,10.3109/02770903.2013.823447,,JOURNAL ARTICLE,,A review on leukotrienes and their receptors with reference to asthma,,,J Asthma,50,9,2013.0,
3410,30473097.0,10.1016/j.molmet.2018.09.009,,JOURNAL ARTICLE,"Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A","LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept",,,Mol Metab,18,,2018.0,3-14
3691,,,BLA:761286,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761286s000lbl.pdf,,,,2023.0,
3675,,,BLA:761334 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761334Orig1s000MultidisciplineR.pdf,,,,2023.0,
363,7527033.0,,,JOURNAL ARTICLE,"Smith BL, Bauer GB, Povirk LF","DNA damage induced by bleomycin, neocarzinostatin, and melphalan in a precisely positioned nucleosome. Asymmetry in protection at the periphery of nucleosome-bound DNA.",,,J. Biol. Chem.,269,48,1994.0,30587-94
53,18570382.0,10.1021/bi800438k,,JOURNAL ARTICLE,,Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex.,,,Biochemistry,,,2008.0,
584,,,NDA:208573,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf,,,,2016.0,
79,15126366.0,10.1158/0008-5472.CAN-03-3403,,JOURNAL ARTICLE,,Characterization of the interaction of ingenol 3-angelate with protein kinase C.,,,Cancer Res,,,2004.0,
271,10794682.0,,,JOURNAL ARTICLE,"Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K","N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration.",,,J. Med. Chem.,43,9,2000.0,1661-3
541,4859983.0,,,JOURNAL ARTICLE,Casdorph HR,"Hypercholesteremia. Treatment with cholestyramine, a bile acid sequestering resin.",,,Calif Med,106,4,1967.0,293-5
266,,,NDA:021536,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021536s031s051lbl.pdf,,,,2015.0,
497,8680742.0,,,JOURNAL ARTICLE,"Prior C, Tian L, el Mallah AI, Young L, Ward JM","Neuromuscular blocking profile of the vecuronium analogue, Org-9487, in the rat isolated hemidiaphragm preparation.",,,Br. J. Pharmacol.,116,7,1995.0,3049-55
411,2139412.0,,,JOURNAL ARTICLE,"Santen RJ, Langecker P, Santner SJ, Sikka S, Rajfer J, Swerdloff R",Potency and specificity of CGS-16949A as an aromatase inhibitor.,,,Endocr. Res.,16,1,1990.0,77-91
99,15212190.0,,,JOURNAL ARTICLE,,Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma,,,Arzneimittelforschung,54,5,2004.0,
43,17588934.0,10.1126/science.1142189,,JOURNAL ARTICLE,,An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.,,,Science,,,2007.0,
113,19751980.0,10.1016/j.bmc.2009.08.024,,JOURNAL ARTICLE,"Aurelio L, Valant C, Figler H, Flynn BL, Linden J, Sexton PM, Christopoulos A, Scammells PJ","3- and 6-Substituted 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridines as A1 adenosine receptor allosteric modulators and antagonists.",,,Bioorg. Med. Chem.,17,20,2009.0,7353-61
649,27144355.0,10.1038/nature17998,,JOURNAL ARTICLE,"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD",NMDAR inhibition-independent antidepressant actions of ketamine metabolites.,,,Nature,533,7604,2016.0,481-6
221,,,BLA:125349,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125349s000lbl.pdf,,,,2012.0,
3712,,,NDA:217603,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217603s000lbl.pdf,,,,2023.0,
3194,,,NDA:212887,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212887s000lbl.pdf,,,,2021.0,
3260,,,EMEA/H/C/005138/0000,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/assessment-report/orladeyo-epar-public-assessment-report_en.pdf,,,,2021.0,
322,,,BLA:103234,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103234s5323lbl.pdf,,,,2013.0,
2745,29061741.0,10.1128/AAC.01454-17,,JOURNAL ARTICLE,"Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, Kohira N, Miyagawa S, Ishibashi N, Matsumoto S, Nakamura R, Tsuji M, Yamano Y","In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria",,,Antimicrob Agents Chemother,62,1,2017.0,e01454-17
416,12177684.0,,,JOURNAL ARTICLE,"Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S",Pharmacology of flibanserin.,,,CNS Drug Rev,8,2,2002.0,117-42
98,8405122.0,,,JOURNAL ARTICLE,,Ca2+(-)dependent and Ca2+(-)independent vasorelaxation induced by cardiotonic phosphodiesterase inhibitors,,,Eur J Pharmacol,240,1,1993.0,
406,,,WOS:A1990DP01300004,JOURNAL ARTICLE,"CAROPPO, R",EFFECT OF NIPEROTIDINE ON HYDROGEN-ION SECRETION AND ELECTRICAL PARAMETERS OF ISOLATED ASTRIC-MUCOSA,,,Curr. Ther. Res.-Clin. Exp.,48,1,1990.0,20-29
3248,,,BLA:761123 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761123Orig1s000MultidisciplineR.pdf,,,,2021.0,
2537,27401242.0,10.1158/1078-0432.CCR-16-0917,,JOURNAL ARTICLE,"Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, Andre F, Soria JC, Friboulet L",Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.,,,Clin. Cancer. Res.,22,24,2016.0,5983-91
324,,,BLA:125058,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125058s220lbl.pdf,,,,2013.0,
503,,,NDA:208434,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf,,,,2015.0,
81,23647933.0,10.1111/jce.12155,,JOURNAL ARTICLE,,Dronedarone's inhibition of If current is the primary mechanism responsible for its bradycardic effect.,,,J Cardiovasc Electrophysiol,,,2013.0,
3687,,,NDA:216023,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216023s000lbl.pdf,,,,2023.0,
2739,,,EMEA/H/C/004587,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/nuceiva-epar-product-information_en.pdf,,,,2019.0,
2738,27026201.0,10.1158/1078-0432.CCR-15-2822,,JOURNAL ARTICLE,"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, Hirai T, Atsumi R, Nakada T, Hayakawa I, Abe Y, Agatsuma T","DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1",,,Clin Cancer Res,22,20,2016.0,5097-5108
2747,,,NDA:206488,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206488lbl.pdf,,,,2019.0,
3673,,,NDA:217759 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217759Orig1s000MultidisciplineR.pdf,,,,2023.0,
2777,,,BLA:761119,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf,,,,2020.0,
2546,27908881.0,10.1182/blood-2016-10-745133,,JOURNAL ARTICLE,"Lee LY, Hernandez D, Rajkhowa T, Smith SC, Raman JR, Nguyen B, Small D, Levis M","Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor",,,Blood,129,2,2017.0,257-60
559,18655903.0,10.1016/S0079-6123(08)00437-8,,JOURNAL ARTICLE,"Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G","Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.",,,Prog. Brain Res.,170,,2008.0,473-512
366,,,EMEA/H/C/001033,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001033/WC500043300.pdf,,,,2015.0,
628,,,NDA:209115,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf,,,,2016.0,
585,,,BLA:103532,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103532s5175lbl.pdf,,,,2014.0,
996,26308095.0,10.1021/acs.jmedchem.5b00726,,JOURNAL ARTICLE,"Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T",Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.,,,J. Med. Chem.,58,18,2015.0,7370-80
2908,,,NDA:213973,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf,,,,2020.0,
556,,,NDA:022127,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022127s011lbl.pdf,,,,2014.0,
2003,,,NDA:210951,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210951s000lbl.pdf,,,,2018.0,
93,23319593.0,10.1074/jbc.M112.412130,,JOURNAL ARTICLE,,Hydralazine and organic nitrates restore impaired excitation-contraction coupling by reducing calcium leak associated with nitroso-redox imbalance,,,J Biol Chem,288,9,2013.0,
629,,10.1021/acs.jmedchem.6b00990,,JOURNAL ARTICLE,"Thorsell, Ann-Gerd and Ekblad, Torun and Karlberg, Tobias and Löw, Mirjam and Pinto, Ana Filipa and Tresaugues, Lionel and Moche, Martin and Cohen, Michael S. and Schüler, Herwig",Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors,,,J. Med. Chem.,,,2016.0,
3378,,,NDA:214012,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf,,,,2021.0,
507,,,NDA:207947,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207947s000lbl.pdf,,,,2015.0,
677,,,NDA:208383,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf,,,,2017.0,
3394,,,NDA:208712 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/208712Orig1s000IntegratedR.pdf,,,,2022.0,
603,6141283.0,,,JOURNAL ARTICLE,"Spiegel K, Pasternak GW",Meptazinol: a novel Mu-1 selective opioid analgesic.,,,J. Pharmacol. Exp. Ther.,228,2,1984.0,414-9
413,,,NDA:019385,DRUG LABEL,,,,"http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf",,,,2003.0,
297,,,NDA:205123,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205123s008lbl.pdf,,,,2015.0,
196,,,NDA:207500,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf,,,,2015.0,
3086,,,NDA:206966,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf,,,,2020.0,
516,19833635.0,10.1093/jac/dkp370,,JOURNAL ARTICLE,"Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR","In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.",,,J. Antimicrob. Chemother.,64,6,2009.0,1226-9
3543,,,BLA:761183 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761183Orig1s000PharmR.pdf,,,,2022.0,
283,2858236.0,,,JOURNAL ARTICLE,"Dukes ID, Vaughan Williams EM","Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile.",,,Br. J. Pharmacol.,84,2,1985.0,365-80
267,,,EMEA/H/C/001012,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001012/WC500053998.pdf,,,,2014.0,
3237,,,NDA:215498 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215498Orig1s000IntegratedR.pdf,,,,2021.0,
20,17293563.0,10.1124/jpet.106.115840,,JOURNAL ARTICLE,,"Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.",,,J Pharmacol Exp Ther,,,2007.0,
3203,20446681.0,10.1021/jm100181s,,JOURNAL ARTICLE,"Bolli MH, Abele S, Binkert C, Bravo R, Buchmann S, Bur D, Gatfield J, Hess P, Kohl C, Mangold C, Mathys B, Menyhart K, Muller C, Nayler O, Scherz M, Schmidt G, Sippel V, Steiner B, Strasser D, Treiber A, Weller T","2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists",,,J Med Chem,53,10,2010.0,4198-4211
32,19317446.0,10.1021/jm801601v,,JOURNAL ARTICLE,,Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists.,,,J Med Chem,,,2009.0,
307,1696381.0,,,JOURNAL ARTICLE,"Fujii M, Okabayashi Y, Nakamura T, Tani S, Fujisawa T, Otsuki M","Action of a new cholinergic agonist, aclatonium napadisilate, on isolated rat pancreatic acini.",,,Pancreas,5,4,1990.0,427-33
3664,,,NDA:216059,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216059Orig1s000Corrected_lbl.pdf,,,,2023.0,
3234,,,NDA:214429 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214429Orig1s000MultidisciplineR.pdf,,,,2021.0,
536,2154989.0,,,JOURNAL ARTICLE,"Morii M, Takata H, Fujisaki H, Takeguchi N","The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor.",,,Biochem. Pharmacol.,39,4,1990.0,661-7
3211,18464023.0,10.1080/13697130802073425,,JOURNAL ARTICLE,"Coelingh Bennink HJ, Holinka CF, Diczfalusy E",Estetrol review: profile and potential clinical applications,,,Climacteric,11,1,2008.0,47-58
381,,,NDA:206038,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf,,,,2015.0,
523,,,NDA:019998,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019998s013lbl.pdf,,,,2007.0,
547,22455413.0,10.1056/NEJMoa1109997,,JOURNAL ARTICLE,"Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S",Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.,,,N. Engl. J. Med.,366,13,2012.0,1190-9
3558,,,EMEA/H/C/005638 review,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/assessment-report/sunlenca-epar-public-assessment-report_en.pdf,,,,2022.0,
352,,,NDA:206426,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206426lbl.pdf,,,,2014.0,
2006,,,NDA:208700,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208700s000lbl.pdf,,,,2018.0,
3049,32880805.0,10.1007/s40265-020-01384-y,,JOURNAL ARTICLE,Dhillon S,Daprodustat: first approval,,,Drugs,80,14,2020.0,1491-1497
2566,25651699.0,10.14411/fp.2014.068,,JOURNAL ARTICLE,"Verma M, Pathak M, Shahab M, Singh K, Mitra K, Misra-Bhattacharya S",Moxidectin causes adult worm mortality of human lymphatic filarial parasite Brugia malayi in rodent models,,,Folia Parasitol (Praha),61,6,2014.0,561-70
296,,,BLA:125427,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf,,,,2014.0,
201,,,BLA:125326,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125326s060lbl.pdf,,,,2014.0,
198,,,EMEA/H/C/000773,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000773/WC500045832.pdf,,,,2014.0,
632,20363976.0,10.4049/jimmunol.0902819,,JOURNAL ARTICLE,"Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K",Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.,,,J. Immunol.,184,9,2010.0,5298-307
2912,,,BLA:761142,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761142s000lbl.pdf,,,,2020.0,
443,8891469.0,,,JOURNAL ARTICLE,"Noble S, McTavish D",Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction.,,,Drugs,52,4,1996.0,589-605
3702,,,BLA:761345,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345s000lbl.pdf,,,,2023.0,
3524,,,BLA:761244 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761244Orig1s000MultidisciplineR.pdf,,,,2022.0,
3233,,,NDA:215341 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf,,,,2021.0,
3395,9067315.0,,,JOURNAL ARTICLE,"Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ, White HS, Wolf HH, Mirsadeghi S, Tahir SH, Bolger MB, Lan NC, Gee KW","Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid A receptor",,,J Pharmacol Exp Ther,280,3,1997.0,1284-1295
383,26131937.0,10.1038/nature14610,,JOURNAL ARTICLE,"Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL",Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.,,,Nature,,,2015.0,
109,,,EMEA/H/C/000916,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000916/WC500038317.pdf,,,,2014.0,
260,,,NDA:021174,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021174s020lbl.pdf,,,,2006.0,
310,,,EMEA/H/C/002055,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002055/WC500127968.pdf,,,,2014.0,
15,20565075.0,10.1021/jm100541c,,JOURNAL ARTICLE,,"Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.",,,J Med Chem,,,2010.0,
301,21828261.0,10.1124/jpet.111.185314,,JOURNAL ARTICLE,"Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, Sachs G","Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).",,,J. Pharmacol. Exp. Ther.,339,2,2011.0,412-20
173,17943726.0,,,JOURNAL ARTICLE,"Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M","E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.",,,Int. J. Cancer,122,3,2008.0,664-71
2776,24987056.0,10.1158/1078-0432.CCR-14-0695,,JOURNAL ARTICLE,"Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallee F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, Dumontet C, Plesa A, Chiron M, Lejeune P, Chittenden T, Park PU, Blanc V","SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies",,,Clin Cancer Res,20,17,2014.0,4574-4583
368,,,NDA:012911,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012911Orig1s033lbl.pdf,,,,2013.0,
2919,24520856.0,10.1021/jm401856k,,JOURNAL ARTICLE,"Ferraris D, Duvall B, Delahanty G, Mistry B, Alt J, Rojas C, Rowbottom C, Sanders K, Schuck E, Huang KC, Redkar S, Slusher BB, Tsukamoto T","Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase",,,J Med Chem,57,6,2014.0,2582–2588
2588,31161538.0,10.1007/s40265-019-01142-9,,JOURNAL ARTICLE,Markham A,Erdafitinib: First global approval,,,Drugs,79,9,2019.0,1017-21
3069,30937733.0,10.1007/s40265-019-01105-0,,JOURNAL ARTICLE,Markham A,Relugolix: first global approval,,,Drugs,79,6,2019.0,675–679
376,22042473.0,10.1097/SLA.0b013e318236bc0f,,JOURNAL ARTICLE,"Fendrich V, Wiese D, Waldmann J, Lauth M, Heverhagen AE, Rehm J, Bartsch DK",Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms.,,,Ann. Surg.,254,5,2011.0,818-23; discussion 823
27,2164086.0,,,JOURNAL ARTICLE,,"BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions.",,,J Pharmacol Exp Ther,,,1990.0,
250,,,NDA:206619,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206619s003lbl.pdf,,,,2015.0,
393,,,NDA:021106,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021106s036lbl.pdf,,,,2013.0,
2773,,,NDA:212801,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf,,,,2020.0,
3703,,,BLA:761342,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761342s000lbl.pdf,,,,2023.0,
639,,,NDA:203094,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203094s005lbl.pdf,,,,2016.0,
3245,16134951.0,10.1021/jm0402162,,JOURNAL ARTICLE,"Huang HC, Tremont SJ, Lee LF, Keller BT, Carpenter AJ, Wang CC, Banerjee SC, Both SR, Fletcher T, Garland DJ, Huang W, Jones C, Koeller KJ, Kolodziej SA, Li J, Manning RE, Mahoney MW, Miller RE, Mischke DA, Rath NP, Reinhard EJ, Tollefson MB, Vernier WF, Wagner GM, Rapp SR, Beaudry J, Glenn K, Regina K, Schuh JR, Smith ME, Trivedi JS, Reitz DB","Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 2)",,,J Med Chem,48,18,2005.0,5853-5868
130,,,EMEA/H/C/002430,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002430/WC500133771.pdf,,,,2012.0,
332,,,NDA:018780,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018780s150lbl.pdf,,,,2015.0,
3550,,,EMEA/H/C/005304 review,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/assessment-report/beyfortus-epar-public-assessment-report_en.pdf,,,,2022.0,
3075,,,BLA:761169,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761169s000lbl.pdf,,,,2020.0,
430,22497992.0,10.1016/j.pbb.2012.03.021,,JOURNAL ARTICLE,"Duffy RA, Morgan C, Naylor R, Higgins GA, Varty GB, Lachowicz JE, Parker EM","Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.",,,Pharmacol. Biochem. Behav.,102,1,2012.0,95-100
3406,,,BLA:761234 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761234Orig1s000MultidisciplineR.pdf,,,,2022.0,
2703,,,BLA:125586,DRUG LABEL,,,,https://www.fda.gov/media/113279/download,,,,2018.0,
3383,33436577.0,10.1038/s41467-020-20602-5,,JOURNAL ARTICLE,"Kim C, Ryu DK, Lee J, Kim YI, Seo JM, Kim YG, Jeong JH, Kim M, Kim JI, Kim P, Bae JS, Shim EY, Lee MS, Kim MS, Noh H, Park GS, Park JS, Son D, An Y, Lee JN, Kwon KS, Lee JY, Lee H, Yang JS, Kim KC, Kim SS, Woo HM, Kim JW, Park MS, Yu KM, Kim SM, Kim EH, Park SJ, Jeong ST, Yu CH, Song Y, Gu SH, Oh H, Koo BS, Hong JJ, Ryu CM, Park WB, Oh MD, Choi YK, Lee SY",A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein,,,Nat Commun,12,1,2021.0,288
7,19783139.0,10.1016/j.bmcl.2009.08.091,,JOURNAL ARTICLE,,"Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected].",,,Bioorg Med Chem Lett,,,2009.0,
674,21093089.0,10.1016/j.diabres.2010.10.012,,JOURNAL ARTICLE,"Cho JM, Jang HW, Cheon H, Jeong YT, Kim DH, Lim YM, Choi SH, Yang EK, Shin CY, Son MH, Kim SH, Kim HJ, Lee MS",A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.,,,Diabetes Res. Clin. Pract.,91,1,2011.0,72-9
327,12825935.0,,,JOURNAL ARTICLE,"Renaud J, Bischoff SF, Buhl T, Floersheim P, Fournier B, Halleux C, Kallen J, Keller H, Schlaeppi JM, Stark W",Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.,,,J. Med. Chem.,46,14,2003.0,2945-57
392,,,NDA:205422,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205422s000lbl.pdf,,,,2015.0,
504,25349307.0,10.1158/1535-7163.MCT-14-0274,,JOURNAL ARTICLE,"Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H",Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.,,,Mol. Cancer Ther.,13,12,2014.0,2910-8
2780,20847162.0,10.2967/jnumed.110.075648,,JOURNAL ARTICLE,"Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, Franssen GM, Versleijen-Jonkers YM, Oyen WJ, van der Graaf WT, Boerman OC",ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model,,,J Nucl Med,51,10,2010.0,1565-1572
214,6782492.0,,,JOURNAL ARTICLE,"Schrör K, Sauerland S, Kuhn A, Rösen R",Different sensitivities of prostaglandin-cyclooxygenases in blood platelets and coronary arteries against non-steroidal antiinflammatory drugs.,,,Naunyn Schmiedebergs Arch. Pharmacol.,313,1,1980.0,69-76
2937,,,NDA:214787,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf,,,,2020.0,
3244,31020659.0,10.1111/head.13510,,JOURNAL ARTICLE,"Hargreaves R, Olesen J",Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class,,,Headache,59,6,2019.0,951-970
685,,,NDA:209606,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf,,,,2017.0,
601,8736619.0,,,JOURNAL ARTICLE,"Patel SS, Wilde MI",Ebrotidine.,,,Drugs,51,6,1996.0,974-80; discussion 981
2741,30805897.0,10.1007/s40265-019-01077-1,,JOURNAL ARTICLE,Dhillon S,Roxadustat: First Global Approval,,,Drugs,79,5,2019.0,563-572
412,2521224.0,,,JOURNAL ARTICLE,"Santen RJ, Demers LM, Adlercreutz H, Harvey H, Santner S, Sanders S, Lipton A",Inhibition of aromatase with CGS 16949A in postmenopausal women.,,,J. Clin. Endocrinol. Metab.,68,1,1989.0,99-106
2564,,,NDA:210854,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf,,,,2018.0,
220,,,EMEA/H/C/002498,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf,,,,2015.0,
112,15200144.0,10.1016/j.ceca.2003.10.013,,JOURNAL ARTICLE,"Breitwieser GE, Miedlich SU, Zhang M",Calcium sensing receptors as integrators of multiple metabolic signals.,,,Cell Calcium,35,3,2004.0,209-16
3058,31301309.0,10.1016/j.ejphar.2019.172532,,JOURNAL ARTICLE,"Fukui K, Shinozaki Y, Kobayashi H, Deai K, Yoshiuchi H, Matsui T, Matsuo A, Matsushita M, Tanaka T, Nangaku M","JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor",,,Eur J Pharmacol,15,859,2019.0,172532
236,,,NDA:202292,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202292s000lbl.pdf,,,,2012.0,
561,,,NDA:020452,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020452s005lbl.pdf,,,,2010.0,
3399,,,NDA:215888,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215888s000lbl.pdf,,,,2022.0,
3402,,,BLA:761164 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761164Orig1s000PharmR.pdf,,,,2022.0,
659,22711801.0,10.1073/pnas.1204524109,,JOURNAL ARTICLE,"Gregori-Puigjané E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, Marnett L, Roth BL, Shoichet BK",Identifying mechanism-of-action targets for drugs and probes.,,,Proc. Natl. Acad. Sci. U.S.A.,109,28,2012.0,11178-83
3256,,,EMEA/H/C/005255,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/adtralza-epar-product-information_en.pdf,,,,2021.0,
80,2165421.0,10.1016/0005-2728(90)90114-J,,JOURNAL ARTICLE,,Flux-dependent increase in the stoichiometry of charge translocation by mitochondrial ATPase/ATP synthase induced by almitrine.,,,Biochim Biophys Acta,,,1990.0,
653,,,NDA:208447,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf,,,,2017.0,
2578,,,NDA:208711,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf,,,,2019.0,
425,,,BLA:103694,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103694s1008lbl.pdf,,,,2009.0,
2929,,,BLA:761149,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761149s000lbl.pdf,,,,2020.0,
144,,,BLA:103691,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103691s5095lbl.pdf,,,,2011.0,
3053,23553846.0,10.1158/1078-0432.CCR-12-3247,,JOURNAL ARTICLE,"Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Gradler U, Meyring M, Dorsch D, Jaehrling F, Pehl U, Stieber F, Schadt O, Blaukat A",EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors,,,Clin Cancer Res,19,11,2013.0,2941-2951
67,10976457.0,10.1254/fpj.116.63,,JOURNAL ARTICLE,,"[Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia].",,,Nihon Yakurigaku Zasshi,,,2000.0,
532,,,NDA:208261,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208261Orig1s000lbl.pdf,,,,2016.0,
2942,10377218.0,10.1021/jm990030g,,JOURNAL ARTICLE,"Strickland CL, Weber PC, Windsor WT, Wu Z, Le HV, Albanese MM, Alvarez CS, Cesarz D, del Rosario J, Deskus J, Mallams AK, Njoroge FG, Piwinski JJ, Remiszewski S, Rossman RR, Taveras AG, Vibulbhan B, Doll RJ, Girijavallabhan VM, Ganguly AK",Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure−activity relationships,,,J Med Chem,42,12,1999.0,2125–2135
3385,34807428.0,10.1007/s40265-021-01638-3,,JOURNAL ARTICLE,"Deeks ED, Duggan S",Abrocitinib: first approval,,,Drugs,81,18,2021.0,2149-2157
168,,,BLA:125511,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125511s000lbl.pdf,,,,2015.0,
19,20410884.0,10.1038/nature08960,,JOURNAL ARTICLE,,Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.,,,Nature,,,2010.0,
3068,,,NDA:214621,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf,,,,2020.0,
615,24900456.0,10.1021/ml2002482,,JOURNAL ARTICLE,"Zhong M, Gadek TR, Bui M, Shen W, Burnier J, Barr KJ, Hanan EJ, Oslob JD, Yu CH, Zhu J, Arkin MR, Evanchik MJ, Flanagan WM, Hoch U, Hyde J, Prabhu S, Silverman JA, Wright J",Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.,,,ACS Med Chem Lett,3,3,2012.0,203-6
637,26558155.0,10.4292/wjgpt.v6.i4.213,,JOURNAL ARTICLE,"Shailubhai K, Palejwala V, Arjunan KP, Saykhedkar S, Nefsky B, Foss JA, Comiskey S, Jacob GS, Plevy SE","Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.",,,World J Gastrointest Pharmacol Ther,6,4,2015.0,213-22
2943,,,NDA:213793,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793Orig1s000RPLlbl.pdf,,,,2020.0,
686,15715478.0,,,JOURNAL ARTICLE,"Tsou HR, Overbeek-Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD, Michalak RS, Nilakantan R, Discafani C, Golas J, Rabindran SK, Shen R, Shi X, Wang YF, Upeslacis J, Wissner A","Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.",,,J. Med. Chem.,48,4,2005.0,1107-31
3529,,,BLA:761148,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761148Orig1s000Corrected_lbl.pdf,,,,2022.0,
643,,,BLA:125359,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125359s088lbl.pdf,,,,2016.0,
691,,,NDA:209936,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf,,,,2017.0,
122,,,EU/3/08/554,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500005871.pdf,,,,2008.0,
235,15869320.0,,,JOURNAL ARTICLE,,Cilansetron: KC 9946.,,,Drugs R D,6,3,2005.0,169-73
537,11304936.0,,,JOURNAL ARTICLE,"Kwon D, Chae JB, Park CW, Kim YS, Lee SM, Kim EJ, Huh IH, Kim DY, Cho KD","Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.",,,Arzneimittelforschung,51,3,2001.0,204-13
233,,,EMEA/H/C/000666,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000666/WC500021287.pdf,,,,2009.0,
539,9298526.0,,,JOURNAL ARTICLE,"Uneyama H, Takahara A, Dohmoto H, Yoshimoto R, Inoue K, Akaike N",Blockade of N-type Ca2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones.,,,Br. J. Pharmacol.,122,1,1997.0,37-42
2885,13679426.0,10.1523/JNEUROSCI.23-24-08568.2003,,JOURNAL ARTICLE,"Chen M, Dong Y, Simard JM",Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain,,,J Neurosci,23,24,2003.0,8568–8577
3063,,,NDA:214094,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf,,,,2020.0,
3228,,,BLA:761210 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761210Orig1s000MultidisciplineR.pdf,,,,2021.0,
2927,,,BLA:212154,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212154Orig1s000lbl.pdf,,,,2020.0,
40,10461840.0,,,JOURNAL ARTICLE,,"Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections.",,,Int J Antimicrob Agents,,,1999.0,
640,25676420.0,10.1038/leu.2015.42,,JOURNAL ARTICLE,"Zabriskie MS, Vellore NA, Gantz KC, Deininger MW, O'Hare T",Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.,,,Leukemia,29,9,2015.0,1939-42
2783,,,NDA:213411,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf,,,,2020.0,
1800,,,NDA:209803,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf,,,,2017.0,
484,2905151.0,,,JOURNAL ARTICLE,"Vincent J, Sumner DJ, Reid JL",Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects.,,,Br J Clin Pharmacol,26,5,1988.0,503-8
2538,25733882.0,10.1073/pnas.1420785112,,JOURNAL ARTICLE,"Zou HY, Li Q, Engstrom LD, West M, Appleman V, Wong KA, McTigue M, Deng YL, Liu W, Brooun A, Timofeevski S, McDonnell SR, Jiang P, Falk MD, Lappin PB, Affolter T, Nichols T, Hu W, Lam J, Johnson TW, Smeal T, Charest A, Fantin VR",PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.,,,Proc. Natl. Acad. Sci. USA,112,11,2015.0,3493-98
480,18500360.0,10.1038/bjp.2008.198,,JOURNAL ARTICLE,"Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H","Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.",,,Br. J. Pharmacol.,154,8,2008.0,1662-71
39,18678486.0,10.1016/j.bmcl.2008.07.088,,JOURNAL ARTICLE,,Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.,,,Bioorg Med Chem Lett,,,2008.0,
3230,,,BLA:761210,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf,,,,2021.0,
277,,,NDA:019734,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022276s003lbl.pdf,,,,2014.0,
3538,27714851.0,10.1111/exd.13236,,JOURNAL ARTICLE,"Oyama S, Kitamura H, Kuramochi T, Higuchi Y, Matsushita H, Suzuki T, Goto M, Adachi H, Kasutani K, Sakamoto A, Iwayanagi Y, Kaneko A, Nanami M, Fujii E, Esaki K, Takashima Y, Shimaoka S, Hattori K, Kawabe Y",Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody,,,Exp Dermatol,27,1,2018.0,14-21
94,19466525.0,10.1007/s00380-008-1106-1,,JOURNAL ARTICLE,,"Effect of edaravone, a novel free radical scavenger, supplemented to cardioplegia on myocardial function after cardioplegic arrest: in vitro study of isolated rat heart",,,Heart Vessels,24,3,2009.0,
1901,,,NDA:209360,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209360s000lbl.pdf,,,,2017.0,
3523,,,BLA:761244,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf,,,,2022.0,
3421,,,NDA:215272,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf,,,,2022.0,
2762,32253226.0,10.1126/scitranslmed.abb5883,,JOURNAL ARTICLE,"Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schafer A, Dinnon KH, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS",An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice,,,Sci Transl Med,,,2020.0,eabb5883
554,,,ANDA:077394,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/077394lbl.pdf,,,,2005.0,
2784,32241871.0,10.1158/1535-7163.MCT-19-0873,,JOURNAL ARTICLE,"Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, Forero-Torres A, Peterson S",Preclinical activity of HER2-Selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models,,,Mol Cancer Ther,19,4,2020.0,976-987
76,1775162.0,10.1016/0166-6851(91)90062-B,,JOURNAL ARTICLE,,Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action.,,,Mol Biochem Parasitol,,,1991.0,
662,,,NDA:207997,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997Orig1Orig2s000lbl.pdf,,,,2017.0,
498,7551370.0,,,JOURNAL ARTICLE,"Hozawa S, Haruta Y, Ishioka S, Yamakido M","Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma.",,,Am. J. Respir. Crit. Care Med.,152,4 Pt 1,1995.0,1198-202
316,,,NDA:021141,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21176lbl.pdf,,,,2000.0,
2555,,,BLA:761063,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761063s000lbl.pdf,,,,2018.0,
12,22959556.0,10.1016/j.bmc.2012.08.012,,JOURNAL ARTICLE,,"Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-y lcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.",,,Bioorg Med Chem,,,2012.0,
563,,,NDA:020221,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020221s024lbl.pdf,,,,2008.0,
2312,,,NDA:761067,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf,,,,2018.0,
222,,10.1111/j.1527-3458.1998.tb00067.x,,JOURNAL ARTICLE,"Kojima, Jun; Onodera, Kenji; Ozeki, Mitsuo; Nakayama, Kunio",Ipidacrine (NIK-247): A Review of Multiple Mechanisms as an Antidementia Agent,,,CNS Drug Reviews,4,3,1998.0,247-59
3548,,,NDA:216340,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf,,,,2022.0,
5,18500680.0,10.1055/s-2008-1076699,,JOURNAL ARTICLE,,"Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats.",,,Horm Metab Res,,,2008.0,
635,27357069.0,10.1007/s40265-016-0606-z,,JOURNAL ARTICLE,Kim ES,Olmutinib: First Global Approval.,,,Drugs,76,11,2016.0,1153-7
1801,10193788.0,,,JOURNAL ARTICLE,"Vanderheyden PM, Fierens FL, De Backer JP, Fraeyman N, Vauquelin G",Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.,,,Br. J. Pharmacol.,126,4,1999.0,1057-65
280,3114201.0,,,JOURNAL ARTICLE,"Tatsumi K, Fukushima M, Shirasaka T, Fujii S","Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.",,,Jpn. J. Cancer Res.,78,7,1987.0,748-55
2759,,10.1101/2020.03.11.987016,,JOURNAL ARTICLE,"Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, Shimojima M, Fukushi S",The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15,,,bioRxiv,,,2020.0,
2571,,,NDA:211172,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211172lbl.pdf,,,,2018.0,
3561,,,NDA:208171,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208171s000lbl.pdf,,,,2022.0,
3696,,,EMEA/H/C/004867 review,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/assessment-report/sohonos-epar-refusal-public-assessment-report_en.pdf,,,,2023.0,
506,26291199.0,10.1021/acs.jmedchem.5b00698,,JOURNAL ARTICLE,"Asaki T, Kuwano K, Morrison K, Gatfield J, Hamamoto T, Clozel M",Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.,,,J. Med. Chem.,58,18,2015.0,7128-37
379,,,NDA:021839,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021839s016lbl.pdf,,,,2014.0,
2711,,,NDA:211675,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf,,,,2019.0,
2525,29274361.0,10.1016/j.exphem.2017.12.005,,JOURNAL ARTICLE,"Yoshida H, Yamada H, Nogami W, Dohi K, Kurino-Yamada T, Sugiyama K, Takahashi K, Gahara Y, Kitaura M, Hasegawa M, Oshima I, Kuwabara K.","Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl",,,Exp. Hematol.,59,,2018.0,30-39.e2
2884,26934220.0,10.1038/nature17180,,,"Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR5, Flint M, McMullan LK, Chen SS, Fearns R5, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S",Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys,,,Nature,531,7594,2016.0,381–385
3668,,,NDA:216403,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216403s000lbl.pdf,,,,2023.0,
2708,,,NDA:212862,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf,,,,2019.0,
275,,,BLA:103353,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103353s5184lbl.pdf,,,,2015.0,
210,3000389.0,,,JOURNAL ARTICLE,"Takeyama K, Minato H, Fukuya F, Kawahara S, Hosoki K, Kadokawa T","Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs.",,,Arzneimittelforschung,35,10,1985.0,1502-7
3535,25416789.0,10.1158/1535-7163.MCT-14-0219,,JOURNAL ARTICLE,"Ohkubo S, Kodama Y, Muraoka H, Hitotsumachi H, Yoshimura C, Kitade M, Hashimoto A, Ito K, Gomori A, Takahashi K, Shibata Y, Kanoh A, Yonekura K","TAS-116, a highly selective inhibitor of heat shock protein 90alpha and beta, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models",,,Mol Cancer Ther,14,1,2015.0,14-22
2922,,,BLA:761158 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761158Orig1s000MultidisciplineR.pdf,,,,2020.0,
2910,,,NDA:212155,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212155s000lbl.pdf,,,,2020.0,
3223,,,NDA:214622,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf,,,,2021.0,
2752,,10.26434/chemrxiv.12039888.v1,,JOURNAL ARTICLE,"Xu Z, Yao H, Shen J, Wu N, Xu Y, Lu X",Nelfinavir is active against SARS-CoV-2 in Vero E6 cells,,,ChemRxiv,,,2020.0,
3193,28557445.0,10.1021/acs.jmedchem.7b00449,,JOURNAL ARTICLE,"Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster EM, Kretschmer A, Geiss V, Li V, Straub A, Mittendorf J, Jautelat R, Schirok H, Schlemmer KH, Lustig K, Gerisch M, Knorr A, Tinel H, Mondritzki T, Trubel H, Sandner P, Stasch JP",Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure,,,J Med Chem,60,12,2017.0,5146-5161
3205,,,NDA:214231 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214231Orig1s000PharmR.pdf,,,,2021.0,
3379,,,BLA:761195 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761195Orig1s000IntegratedR.pdf,,,,2021.0,
328,22671931.0,10.1111/j.1476-5381.2012.02068.x,,JOURNAL ARTICLE,"Wade PR, Palmer JM, McKenney S, Kenigs V, Chevalier K, Moore BA, Mabus JR, Saunders PR, Wallace NH, Schneider CR, Kimball ES, Breslin HJ, He W, Hornby PJ","Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist.",,,Br. J. Pharmacol.,167,5,2012.0,1111-25
682,,,,JOURNAL ARTICLE,"Bai AP, Guo ZR, Hu WH, Shen F, Cheng GF.","Design, synthesis and in vitro evaluation of a new class of novel cyclooxygenase-2 inhibitors: 3,4-diaryl-3-pyrrolin-2-ones.",,,Chin Chem Lett,12,9,2001.0,775–8
145,,,NDA:020807,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020807s011lbl.pdf,,,,2006.0,
450,21615387.0,10.1111/j.1476-5381.2011.01286.x,,JOURNAL ARTICLE,Schwartz JC,The histamine H3 receptor: from discovery to clinical trials with pitolisant.,,,Br. J. Pharmacol.,163,4,2011.0,713-21
3525,,,NDA:214958,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf,,,,2022.0,
3270,34390486.0,10.1007/s40265-021-01578-y,,JOURNAL ARTICLE,Hoy SM,Upacicalcet: first approval,,,Drugs,81,13,2021.0,1593-1596
517,12173241.0,,,JOURNAL ARTICLE,Scholz A,Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels.,,,Br J Anaesth,89,1,2002.0,52-61
544,8287905.0,,,JOURNAL ARTICLE,"Tohse N, Takeda Y, Kanno M",Voltage-dependent modulation of L-type Ca2+ current by manidipine in guinea-pig heart cells.,,,Eur. J. Pharmacol.,249,2,1993.0,231-3
285,21651906.0,10.1016/j.ejphar.2011.05.049,,JOURNAL ARTICLE,"Kawachi M, Matsunaga Y, Tanaka T, Hori Y, Ito K, Nagahama K, Ozaki T, Inoue N, Toda R, Yoshii K, Hirayama M, Kawabata Y, Takei M",Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats.,,,Eur. J. Pharmacol.,666,1-3,2011.0,218-25
680,,,EMEA/H/C/004119,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004119/WC500231261.pdf,,,,2017.0,
333,23083772.0,10.1016/j.jacc.2012.08.986,,JOURNAL ARTICLE,"Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, Stein EA","Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.",,,J. Am. Coll. Cardiol.,60,19,2012.0,1888-98
519,7763301.0,,,JOURNAL ARTICLE,"Coley HM, Brooks N, Phillips DH, Hewer A, Jenkins TC, Jarman M, Judson IR",The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies.,,,Biochem. Pharmacol.,49,9,1995.0,1203-12
3247,,,BLA:761123,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761123s000lbl.pdf,,,,2021.0,
399,10102460.0,,,JOURNAL ARTICLE,"Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmström M, Hägg A, Jonsson T, Lapidus L, Leijd B, Stockelberg D, Säfwenberg U, Taghavi A, Thorsén M","Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.",,,Thromb. Haemost.,81,3,1999.0,358-63
2699,19754199.0,10.1021/jm9007533,,JOURNAL ARTICLE,"Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, Gunawardane RN, Cramer MD, Gardner MF, James J, Zarrinkar PP, Patel HK, Bhagwat SS","Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor",,,J Med Chem,52,23,2009.0,7808-16
606,,,EMEA/H/C/000116,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000116/WC500024979.pdf,,,,2015.0,
3267,29563324.0,10.1124/jpet.117.247551,,JOURNAL ARTICLE,"Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, Kai K, Kitano Y","Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the alpha2delta subunit of voltage-gated calcium channels",,,J Pharmacol Exp Ther,365,3,2018.0,573-582
2526,,,NDA:211109,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf,,,,2018.0,
481,,,BLA:761036,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761036Orig1s000lbledt.pdf,,,,2015.0,
3396,,,NDA:215833,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf,,,,2022.0,
3197,,,NDA:214200,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf,,,,2021.0,
2550,30411311.0,10.1007/s40265-018-1006-3,,JOURNAL ARTICLE,Keam SJ,Vibegron: First Global Approval.,,,Drugs,78,17,2018.0,1835–39
152,,,BLA:125276,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125276s092lbl.pdf,,,,2013.0,
261,,,NDA:020986,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020986s059s081lbl.pdf,,,,2015.0,
651,25941111.0,10.1158/1078-0432.CCR-14-0816,,JOURNAL ARTICLE,"VanArsdale T, Boshoff C, Arndt KT, Abraham RT",Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.,,,Clin. Cancer Res.,21,13,2015.0,2905-10
388,11786663.0,,,JOURNAL ARTICLE,"Fukushima Y, Otsuka H, Ishikawa M, Asano T, Anai M, Katsube T, Ogawa K, Kajiwara T, Ohkawa S, Ishikawa T, Omata M, Saitoh T",Potent and long-lasting action of lafutidine on the human histamine H(2) receptor.,,,Digestion,64,3,2001.0,155-60
216,,,BLA:125085,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125085s305lbl.pdf,,,,2014.0,
181,,,NDA:011757,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011757s103lbl.pdf,,,,2014.0,
23,22058426.0,10.1194/jlr.M021261,,JOURNAL ARTICLE,,Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain.,,,J Lipid Res,,,2012.0,
619,,,BLA:125293,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125293s085lbl.pdf,,,,2016.0,
2706,31383664.0,10.1128/AAC.00564-19,,JOURNAL ARTICLE,"Tooke CL, Hinchliffe P, Lang PA, Mulholland AJ, Brem J, Schofield CJ, Spencer J",Molecular Basis of Class A beta-Lactamase Inhibition by Relebactam,,,Antimicrob Agents Chemother,23,10,2019.0,e00564-19
185,,,NDA:205776,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205776s000lbl.pdf,,,,2014.0,
2918,,,NDA:212576,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212576s000lbl.pdf,,,,2020.0,
58,1830563.0,10.1161/01.HYP.18.1.22,,JOURNAL ARTICLE,,Ro 42-5892 is a potent orally active renin inhibitor in primates.,,,Hypertension,,,1991.0,
2786,,,NDA:213736,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf,,,,2020.0,
69,19153939.0,,,JOURNAL ARTICLE,,"A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction.",,,Pharmacopsychiatry,,,2009.0,
534,7726994.0,,,JOURNAL ARTICLE,"Wouters W, Snoeck E, De Coster R","Vorozole, a specific non-steroidal aromatase inhibitor.",,,Breast Cancer Res. Treat.,30,1,1994.0,89-94
2765,29093181.0,10.1126/scitranslmed.aao1690,,JOURNAL ARTICLE,"Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Schöffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C",A precision therapy against cancers driven by KIT/PDGFRA mutations,,,Sci Transl Med,9,414,2017.0,eaao1690
2726,,,NDA:209500,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf,,,,2019.0,
670,,,NDA:050740,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf,,,,2012.0,
85,9347318.0,10.1016/S0306-3623(97)00258-9,,JOURNAL ARTICLE,,Antagonistic effects of isofloxythepin on dopamine D1 and D2 receptors and behaviors in rats.,,,Gen Pharmacol,,,1997.0,
3195,,,NDA:213176,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf,,,,2021.0,
134,,,,DRUG LABEL,,,,http://www.pmda.go.jp/english/service/pdf/drugs/remitch_jan2009_e.pdf,,,,2009.0,
2556,,,BLA:761097,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf,,,,2018.0,
2772,26990079.0,10.1111/bph.13476,,JOURNAL ARTICLE,"Scott FL, Clemons B, Brooks J, Brahmachary E, Powell R, Dedman H, Desale HG, Timony GA, Martinborough E, Rosen H, Roberts E, Boehm MF, Peach RJ",Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity,,,Br J Pharmacol,173,11,2016.0,1778-1792
302,,,BLA:103946,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103946s5083lbl.pdf,,,,2009.0,
292,,,NDA:021476,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf,,,,2014.0,
2563,,,BLA:761116,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761116s000lbl.pdf,,,,2018.0,
451,,,BLA:125338,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125338s085s087s088lbl.pdf,,,,2015.0,
3082,,,NDA:214103,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214103lbl.pdf,,,,2020.0,
2712,30886973.0,10.1186/s41927-018-0031-x,,JOURNAL ARTICLE,"Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, Camp HS, Padley RJ, George JS, Hyland D, Rosebraugh M, Wishart N, Olson L, Long AJ",In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494),,,BMC Rheumatology,2,23,2018.0,
3071,,,BLA:761150,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf,,,,2020.0,
3695,,,BLA:761309,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf,,,,2023.0,
3393,,,NDA:216196 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf,,,,2022.0,
608,,,BLA:125164,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125164s071s072s073lbl.pdf,,,,2016.0,
3555,,,EMEA/H/C/005442,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/yselty-epar-product-information_en.pdf,,,,2022.0,
3408,,,BLA:761235,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s000lbl.pdf,,,,2022.0,
2925,,,NDA:210730,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210730s000lbl.pdf,,,,2020.0,
2743,29856623.0,10.1021/acs.jmedchem.8b00549,,JOURNAL ARTICLE,"Wu Y, Jiang Z, Li Z, Gu J, You Q, Zhang X","Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia",,,J Med Chem,61,12,2018.0,5332-5349
2936,29657135.0,10.1158/2159-8290.CD-18-0338,,JOURNAL ARTICLE,"Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK",Precision targeted therapy with BLU-667 for RET-driven cancers,,,Cancer Discov,8,7,2018.0,836-849
427,,,NDA:020572,DRUG LABEL,,,,"http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020572s016,020573s015lbl.pdf",,,,2009.0,
2576,,,BLA:761102,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761102s000lbl.pdf,,,,2018.0,
274,,,BLA:125031,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125031s082lbl.pdf,,,,2007.0,
362,1828228.0,,,JOURNAL ARTICLE,"Demicheli C, Albertini JP, Garnier-Suillerot A",Interaction of mithramycin with DNA. Evidence that mithramycin binds to DNA as a dimer in a right-handed screw conformation.,,,Eur. J. Biochem.,198,2,1991.0,333-8
3381,,,BLA:761224,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761224s000lbl.pdf,,,,2021.0,
568,6356910.0,,,JOURNAL ARTICLE,Kerwar SS,Pharmacologic properties of fenbufen.,,,Am. J. Med.,75,4B,1983.0,62-9
3048,32852744.0,10.1007/s40265-020-01383-z,,JOURNAL ARTICLE,Markham A,Vadadustat: first approval,,,Drugs,80,13,2020.0,1365-1371
162,,,US 20080064681 A1,PATENT,"Hidaka, Hiroyoshi; Nishio, Masahiro; Sumi, Kengo",THERAPEUTIC AGENT FOR TREATING GLAUCOMA,,,,,,2008.0,
574,,,EU/3/11/869,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2011/05/WC500106736.pdf,,,,2013.0,
131,14599363.0,,,JOURNAL ARTICLE,"Witte DG, Cassar SC, Masters JN, Esbenshade T, Hancock AA",Use of a fluorescent imaging plate reader--based calcium assay to assess pharmacological differences between the human and rat vanilloid receptor.,,,J Biomol Screen,7,5,2002.0,466-75
577,,,BLA:125509,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125509lbl.pdf,,,,2016.0,
490,5889715.0,,,JOURNAL ARTICLE,Gilmour SJ,Clinical trial of mebanazine--a new monoamine oxidase inhibitor.,,,Br J Psychiatry,111,478,1965.0,899-902
518,,,NDA:201444,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201444s000lbl.pdf,,,,2011.0,
263,,,BLA:125486,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125486_s008lbl.pdf,,,,2014.0,
631,,,NDA:207695,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207695s000lbl.pdf,,,,2016.0,
320,6186851.0,,,JOURNAL ARTICLE,"Levine SN, Hollier B",Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities.,,,J. Cardiovasc. Pharmacol.,5,1,,151-6
693,28949138.0,10.1021/acs.jmedchem.7b01072,,JOURNAL ARTICLE,"Lynagh T, Romero-Rojo JL, Lund C, Pless SA",Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.,,,J. Med. Chem.,,,2017.0,
583,23291630.0,10.1038/nm.3048,,JOURNAL ARTICLE,"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW","ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.",,,Nat. Med.,19,2,2013.0,202-8
2904,21918175.0,10.1158/1078-0432.CCR-11-1157,,JOURNAL ARTICLE,"Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, Fridman JS, Behshad E, Wynn R, Li Y, Boer J, Diamond S, He C, Xu M, Zhuo J, Yao W, Newton RC, Scherle PA","A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3",,,Clin Cancer Res,17,22,2011.0,7127-7138
3541,,,BLA:761310,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf,,,,2022.0,
2926,23300227.0,10.1124/jpet.112.201616,,JOURNAL ARTICLE,"DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW, Violin JD",A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine,,,J Pharmacol Exp Ther,344,3,2013.0,708-717
3391,,,EMEA/H/C/005437,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/vumerity-epar-product-information_en.pdf,,,,2021.0,
179,,,EMEA/H/C/000532,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000532/WC500040171.pdf,,,,2015.0,
96,10427.0,,,JOURNAL ARTICLE,Harms HH,Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors,,,J Pharmacol Exp Ther,199,2,1976.0,
228,,,BLA:125261,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125261s114lbl.pdf,,,,2014.0,
596,15627429.0,,,JOURNAL ARTICLE,"Thierry C, Boeynaems JM, Paolo M",Actions of tilidine and nortilidine on cloned opioid receptors.,,,Eur. J. Pharmacol.,506,3,2005.0,205-8
446,24900486.0,10.1021/ml300049d,,JOURNAL ARTICLE,"Rice KD, Aay N, Anand NK, Blazey CM, Bowles OJ, Bussenius J, Costanzo S, Curtis JK, Defina SC, Dubenko L, Engst S, Joshi AA, Kennedy AR, Kim AI, Koltun ES, Lougheed JC, Manalo JC, Martini JF, Nuss JM, Peto CJ, Tsang TH, Yu P, Johnston S",Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973).,,,ACS Med Chem Lett,3,5,2012.0,416-21
2902,,,BLA:761115,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761115Orig1s000MultidisciplineR.pdf,,,,2020.0,
440,,,NDA:204370,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf,,,,2015.0,
2587,,,NDA:212018,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf,,,,2019.0,
642,28041831.0,10.1016/j.bmcl.2016.12.053,,JOURNAL ARTICLE,"Goldberg DR, De Lombaert S, Aiello R, Bourassa P, Barucci N, Zhang Q, Paralkar V, Stein AJ, Holt M, Valentine J, Zavadoski W",Optimization of spirocyclic proline tryptophan hydroxylase-1 inhibitors.,,,Bioorg. Med. Chem. Lett.,27,3,2017.0,413-419
566,3025043.0,,,JOURNAL ARTICLE,"Yoshida T, Nishioka H, Yoshioka K, Nakano K, Kondo M, Terashima H",Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.,,,Diabetes,36,1,1987.0,6-13
118,16274260.0,,,JOURNAL ARTICLE,,"Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity",,,Drugs R D,6,6,2005.0,371-84
3544,,,BLA:761183,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761183s000lbl.pdf,,,,2022.0,
78,15494035.0,10.1042/BST0320865,,JOURNAL ARTICLE,,Amylin receptors: molecular composition and pharmacology.,,,Biochem Soc Trans,,,2004.0,
238,,,BLA:103976,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103976s5161lbl.pdf,,,,2014.0,
433,2001448.0,,,JOURNAL ARTICLE,Gasson JC,Molecular physiology of granulocyte-macrophage colony-stimulating factor.,,,Blood,77,6,1991.0,1131-45
120,1983712.0,,,JOURNAL ARTICLE,,The effect of the H2-antagonist niperotidine on intragastric acidity in healthy subjects undergoing 24-hour pH-monitoring,,,Ital J Gastroenterol,22,5,1990.0,291-4
2007,,,NDA:205598,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205598s000lbl.pdf,,,,2017.0,
176,12090787.0,,,JOURNAL ARTICLE,"Handley DA, Senanayake CH, Dutczak W, Benovic JL, Walle T, Penn RB, Wilkinson HS, Tanoury GJ, Andersson RG, Johansson F, Morley J",Biological actions of formoterol isomers.,,,Pulm Pharmacol Ther,15,2,2002.0,135-45
551,9126675.0,,,JOURNAL ARTICLE,Scholz H,Pharmacological aspects of calcium channel blockers.,,,Cardiovasc Drugs Ther,10 Suppl 3,,1997.0,869-72
2935,,,NDA:213721,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf,,,,2020.0,
3404,,,BLA:761228,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761228s000lbl.pdf,,,,2022.0,
126,17030736.0,,,JOURNAL ARTICLE,"Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, Salvati P, Fariello RG",Safinamide: from molecular targets to a new anti-Parkinson drug.,,,Neurology,67,7 Suppl 2,2006.0,S18-23
136,,,NDA:022036,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022036lbl.pdf,,,,2010.0,
2539,,,NDA:210598,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf,,,,2018.0,
3066,,,NDA:214094 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf,,,,2020.0,
2572,24002361.0,10.1038/ja.2013.86,,JOURNAL ARTICLE,"Butler MS, Blaskovich MA, Cooper MA",Antibiotics in the clinical pipeline in 2013,,,J Antibiot (Tokyo),66,10,2013.0,571-91
279,21668582.0,10.1111/j.1349-7006.2011.02004.x,,JOURNAL ARTICLE,"Sakata K, Someya M, Matsumoto Y, Tauchi H, Kai M, Toyota M, Takagi M, Hareyama M, Fukushima M","Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination.",,,Cancer Sci.,102,9,2011.0,1712-6
2899,26589308.0,10.1208/s12248-015-9845-2,,JOURNAL ARTICLE,"Hosey CM, Chan R, Benet LZ","BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs",,https://link.springer.com/content/pdf/10.1208/s12248-015-9845-2.pdf,The AAPS journal,18,1,2016.0,251-260
3376,,,NDA:214907 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf,,,,2021.0,
3084,,,EMEA/H/C/004854 report,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/assessment-report/hepcludex-epar-public-assessment-report_en.pdf,,,,2020.0,
3201,,,NDA:214383,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214383s000lbl.pdf,,,,2021.0,
371,,,NDA:020718,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020718s037lbl.pdf,,,,2013.0,
633,22959248.0,10.1016/j.bmcl.2012.06.067,,JOURNAL ARTICLE,"Hu S, Xie G, Zhang DX, Davis C, Long W, Hu Y, Wang F, Kang X, Tan F, Ding L, Wang Y",Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.,,,Bioorg. Med. Chem. Lett.,22,19,2012.0,6301-5
496,18258787.0,10.1096/fj.07-099424,,JOURNAL ARTICLE,"Shorter K, Farjo NP, Picksley SM, Randall VA","Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil.",,,FASEB J.,22,6,2008.0,1725-36
336,2863192.0,,,JOURNAL ARTICLE,"Loewe CJ, Grider JR, Gardiner J, Vlahcevic ZR",Selective inhibition of pentagastrin- and cholecystokinin-stimulated exocrine secretion by proglumide.,,,Gastroenterology,89,4,1985.0,746-51
48,24320933.0,10.1021/jm401499g,,JOURNAL ARTICLE,,"Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection.",,,J Med Chem,,,2014.0,
127,,,NDA:022275,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022275s014lbl.pdf,,,,2014.0,
72,21669536.0,10.1016/j.bmc.2011.05.033,,JOURNAL ARTICLE,,Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.,,,Bioorg Med Chem,,,2011.0,
429,11556519.0,,,JOURNAL ARTICLE,"Henrotin Y, de Leval X, Mathy-Hartet M, Mouithys-Mickalad A, Deby-Dupont G, Dogné JM, Delarge J, Reginster JY",In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators.,,,Inflamm. Res.,50,8,2001.0,391-9
530,20040696.0,10.1345/aph.1M347,,JOURNAL ARTICLE,"Gish EC, Miller JL, Honey BL, Johnson PN","Lofexidine, an {alpha}2-receptor agonist for opioid detoxification.",,,Ann Pharmacother,44,2,2010.0,343-51
573,,,NDA:207155,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207155s000lbl.pdf,,,,2016.0,
74,6148400.0,10.1111/j.2042-7158.1984.tb04449.x,,JOURNAL ARTICLE,,Determination of biological activity of adinazolam and its metabolites.,,,J Pharm Pharmacol,,,1984.0,
614,2853885.0,,,JOURNAL ARTICLE,"Scherman D, Hamon M, Gozlan H, Henry JP, Lesage A, Masson M, Rumigny JF",Molecular pharmacology of niaprazine.,,,Prog. Neuropsychopharmacol. Biol. Psychiatry,12,6,1988.0,989-1001
3526,31318208.0,10.1021/acs.jmedchem.9b00444,,JOURNAL ARTICLE,"Wrobleski ST, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J, Tokarski JS, Strnad J, Zupa-Fernandez A, Cheng L, Shuster D, Gillooly K, Yang X, Heimrich E, McIntyre KW, Chaudhry C, Khan J, Ruzanov M, Tredup J, Mulligan D, Xie D, Sun H, Huang C, D'Arienzo C, Aranibar N, Chiney M, Chimalakonda A, Pitts WJ, Lombardo L, Carter PH, Burke JR, Weinstein DS",Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165,,,J Med Chem,62,20,2019.0,8973-8995
2723,,,NDA:213137,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf,,,,2019.0,
186,,,NDA:020920,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/20920s033lbl.pdf,,,,2013.0,
3398,25224009.0,,,JOURNAL ARTICLE,"Warrilow AG, Hull CM, Parker JE, Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Kelly DE, Kelly SL",The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme,,,Antimicrob Agents Chemother,58,12,2014.0,7121-7127
253,,,NDA:206143,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206143Orig1s000lbl.pdf,,,,2015.0,
669,,,ANDA:064047,DRUG LABEL,,,,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7aa0bae-255b-4792-a963-6606370a175f,,,,2009.0,
595,21762037.0,10.1517/14728222.2011.600692,,JOURNAL ARTICLE,Antoniu SA,Terguride for pulmonary arterial hypertension.,,,Expert Opin. Ther. Targets,15,11,2011.0,1333-5
2532,,,NDA:209816,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf,,,,2018.0,
570,,,BLA:103767,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103767s5119lbl.pdf,,,,2011.0,
424,16004599.0,,,JOURNAL ARTICLE,Jenner P,"Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.",,,Expert Opin Investig Drugs,14,6,2005.0,729-38
3546,31971798.0,10.1021/acs.jmedchem.9b01423,,JOURNAL ARTICLE,"Caravella JA, Lin J, Diebold RB, Campbell AM, Ericsson A, Gustafson G, Wang Z, Castro J, Clarke A, Gotur D, Josephine HR, Katz M, Kershaw M, Yao L, Toms AV, Barr KJ, Dinsmore CJ, Walker D, Ashwell S, Lu W","Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor",,,J Med Chem,63,4,2020.0,1612-1623
212,2484083.0,,,JOURNAL ARTICLE,"DeForrest JM, Waldron TL, Krapcho J, Turk C, Rubin B, Powell JR, Cushman DW, Petrillo EW","Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme.",,,J. Cardiovasc. Pharmacol.,13,6,1989.0,887-94
546,,,EMEA/H/C/000802,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000802/WC500026565.pdf,,,,2016.0,
318,,,NDA:021271,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021271s006lbl.pdf,,,,2014.0,
658,,,NDA:209241,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf,,,,2017.0,
326,,,BLA:125460,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125460s000lbl.pdf,,,,2014.0,
2939,,,BLA:761156,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761156s000lbl.pdf,,,,2020.0,
375,23063522.0,10.1016/j.bmc.2012.09.030,,JOURNAL ARTICLE,"Wang J, Mook RA, Lu J, Gooden DM, Ribeiro A, Guo A, Barak LS, Lyerly HK, Chen W",Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.,,,Bioorg. Med. Chem.,20,22,2012.0,6751-7
2924,32936437.0,10.1007/s40265-020-01404-x,,JOURNAL ARTICLE,Markham A,Belantamab Mafodotin: First Approval,,,Drugs,80,15,2020.0,1607-1613
398,6121964.0,,,JOURNAL ARTICLE,Walshe JM,Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.,,,Lancet,1,8273,1982.0,643-7
2720,,,NDA:213217,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf,,,,2019.0,
119,1620298.0,,,JOURNAL ARTICLE,,"Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage",,,Neurosurgery,30,3,1992.0,358-63
3227,24323472.0,10.1128/AAC.02145-13,,JOURNAL ARTICLE,"Jimenez-Ortigosa C, Paderu P, Motyl MR, Perlin DS",Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates,,,Antimicrob Agents Chemother,58,2,2014.0,1248-1251
2419,26559125.0,10.1124/jpet.115.227793,,JOURNAL ARTICLE,"Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C","Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor.",,,J. Pharmacol. Exp. Ther.,356,1,2016.0,223-31
148,15331566.0,,,JOURNAL ARTICLE,"Baggio LL, Huang Q, Brown TJ, Drucker DJ","A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.",,,Diabetes,53,9,2004.0,2492-500
192,,,BLA:125390,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf,,,,2014.0,
3715,37449459.0,10.1021/acs.jmedchem.3c00481,,JOURNAL ARTICLE,"Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K",DruMAP:A Novel Drug Metabolism and Pharmacokinetics Analysis Platform,,,J Med Chem,66,14,2023.0,9697–9709
68,2572952.0,10.1016/0024-3205(89)90040-4,,JOURNAL ARTICLE,,"The partial opiate receptor agonists, dezocine and ciramadol act as mu receptor antagonists at the feline ileocecal sphincter.",,,Life Sci,,,1989.0,
3087,8035423.0,10.1021/jm00040a008,,JOURNAL ARTICLE,"Rosowsky A, Bader H, Wright JE, Keyomarsi K, Matherly LH","Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin",,,J Med Chem,37,14,1994.0,2167-2174
47,16332435.0,10.1016/j.bmcl.2005.11.047,,JOURNAL ARTICLE,,"Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists.",,,Bioorg Med Chem Lett,,,2006.0,
3380,,,BLA:761195,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761195s000lbl.pdf,,,,2021.0,
2316,19183407.0,10.1111/j.1600-0609.2008.01198.x,,JOURNAL ARTICLE,"Fukushima-Shintani M, Suzuki K, Iwatsuki Y, Abe M, Sugasawa K, Hirayama F, Kawasaki T, Nakahata T",AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist.,,,Eur. J. Haematol.,82,4,2009.0,247-54
3701,35626122.0,10.3390/cancers14102518,,JOURNAL ARTICLE,"Wu L, Huang Y, Sienkiewicz J, Sun J, Guiang L, Li F, Yang L, Golubovskaya V",Bispecific BCMA-CD3 antibodies block multiple myeloma tumor growth,,,Cancers (Basel),14,10,2022.0,2518
2709,,,NDA:212725,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf,,,,2019.0,
140,15322733.0,,,JOURNAL ARTICLE,"Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M","Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.",,,Naunyn Schmiedebergs Arch. Pharmacol.,370,2,2004.0,114-23
515,21771637.0,10.1016/j.mce.2011.06.025,,JOURNAL ARTICLE,"Kolkhof P, Borden SA",Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics.,,,Mol. Cell. Endocrinol.,350,2,2012.0,310-7
255,,,NDA:203214,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203214s007lbl.pdf,,,,2014.0,
234,,,BLA:125104,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125104s840s847s889lbl.pdf,,,,2013.0,
681,17553678.0,10.1016/j.bmcl.2007.05.066,,JOURNAL ARTICLE,"Yamazaki Y, Abe K, Toma T, Nishikawa M, Ozawa H, Okuda A, Araki T, Oda S, Inoue K, Shibuya K, Staels B, Fruchart JC",Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.,,,Bioorg. Med. Chem. Lett.,17,16,2007.0,4689-93
3551,,,EMEA/H/C/005304,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/beyfortus-epar-product-information_en.pdf,,,,2022.0,
442,,,NDA:207981,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf,,,,2015.0,
550,16891464.0,,,JOURNAL ARTICLE,"Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, Krett NL, Rosen ST","Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.",,,Mol. Cancer Ther.,5,7,2006.0,1783-9
225,11431468.0,,,JOURNAL ARTICLE,"Chao SH, Price DH",Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo.,,,J. Biol. Chem.,276,34,2001.0,31793-9
418,20840530.0,10.1111/j.1743-6109.2010.02032.x,,JOURNAL ARTICLE,"Stahl SM, Sommer B, Allers KA",Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder.,,,J Sex Med,8,1,2011.0,15-27
339,25765567.0,10.1111/bph.13129,,JOURNAL ARTICLE,"Nassini R, Fusi C, Materazzi S, Coppi E, Tuccinardi T, Marone IM, De Logu F, Preti D, Tonello R, Chiarugi A, Patacchini R, Geppetti P, Benemei S",The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives.,,,Br. J. Pharmacol.,,,2015.0,
3552,,,NDA:215515,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215515s000lbl.pdf,,,,2022.0,
3412,26713839.0,10.1021/acs.molpharmaceut.5b00868,,JOURNAL ARTICLE,"Hershkovitz O, Bar-Ilan  A, Guy  R, Felikman  Y, Moschcovich  L, Hwa  L, Rosenfeld  RG, Fima  E, Hart  G","In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone",,,Mol Pharm,13,2,2016.0,631-639
3215,,,EUA:143603,DRUG LABEL,,,,https://www.fda.gov/media/143603/download,,,,2021.0,
89,4396765.0,,,JOURNAL ARTICLE,,"A comparison of the effects of noradrenaline, adrenaline and some phenylephrine derivatives on alpha-, beta- and beta- adrenergic receptors",,,S Afr Med J,45,10,1971.0,
262,,,BLA:125476,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf,,,,2014.0,
73,17275317.0,10.1016/j.bmc.2007.01.014,,JOURNAL ARTICLE,,Synthesis and structure-activity relationships of novel warfarin derivatives.,,,Bioorg Med Chem,,,2007.0,
2767,,,NDA:212728,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf,,,,2020.0,
3214,,,BLA:761196,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf,,,,2021.0,
2308,,,NDA:021462,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021462lbl.pdf,,,,2004.0,
3389,,,000245006,DRUG LABEL,,,,https://www.pmda.go.jp/files/000245006.pdf,,,,2021.0,
348,10766174.0,,,JOURNAL ARTICLE,"Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH",A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.,,,Cancer Res.,60,7,2000.0,1871-7
389,7703232.0,,,JOURNAL ARTICLE,"Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, Taskinen J",Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.,,,Biochemistry,34,13,1995.0,4202-10
552,17213004.0,,,JOURNAL ARTICLE,"Park JY, Kim KA, Park PW, Lee OJ, Ryu JH, Lee GH, Ha MC, Kim JS, Kang SW, Lee KR","Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study.",,,Clin Ther,28,11,2006.0,1837-47
3085,,,000237990,DRUG LABEL,,,,https://www.pmda.go.jp/files/000237990.pdf,,,,2020.0,
2593,,,BLA:761121,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf,,,,2019.0,
605,,,BLA:103964,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103964s5264lbl.pdf,,,,2015.0,
3251,,,BLA:761208 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761208Orig1s000MultidisciplineR.pdf,,,,2021.0,
270,15017615.0,,,JOURNAL ARTICLE,"Atherton C, Jones J, McKaig B, Bebb J, Cunliffe R, Burdsall J, Brough J, Stevenson D, Bonner J, Rordorf C, Scott G, Branson J, Hawkey CJ","Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study.",,,Clin. Gastroenterol. Hepatol.,2,2,2004.0,113-20
3209,,,BLA:761181 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761181Orig1s000PharmR.pdf,,,,2021.0,
441,6285914.0,,,JOURNAL ARTICLE,"Rosenfeld RG, Aggarwal BB, Hintz RL, Dollar LA",Recombinant DNA-derived methionyl human growth hormone is similar in membrane binding properties to human pituitary growth hormone.,,,Biochem. Biophys. Res. Commun.,106,1,1982.0,202-9
137,2445740.0,,,JOURNAL ARTICLE,"Schmid-Antomarchi H, De Weille J, Fosset M, Lazdunski M",The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells.,,,J. Biol. Chem.,262,33,1987.0,15840-4
1096,,,NDA:209637,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf,,,,2017.0,
470,17652911.0,,,JOURNAL ARTICLE,"Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M","Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.",,,J. Pharmacol. Sci.,104,3,2007.0,263-73
1198,26641137.0,10.1056/NEJMoa1509981,,JOURNAL ARTICLE,"Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR",Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.,,,N. Engl. J. Med.,374,4,2016.0,323-32
395,20600305.0,10.1016/j.pharmthera.2010.06.002,,JOURNAL ARTICLE,Millan MJ,"From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.",,,Pharmacol. Ther.,128,2,2010.0,229-73
575,,,BLA:125288,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125288s062lbl.pdf,,,,2014.0,
299,,,EMEA/H/C/002556,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002556/WC500148380.pdf,,,,2015.0,
995,,,BLA:761070,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf,,,,2017.0,
153,23253932.0,10.1136/annrheumdis-2012-202371,,JOURNAL ARTICLE,"Patel DD, Lee DM, Kolbinger F, Antoni C",Effect of IL-17A blockade with secukinumab in autoimmune diseases.,,,Ann. Rheum. Dis.,72 Suppl 2,,2013.0,ii116-23
169,8483969.0,,,JOURNAL ARTICLE,"Blandizzi C, Mengozzi G, Intorre L, Natale G, Soldani G, Del Tacca M",Inhibitory cholinergic effects of esaprazole on gastric secretion and plasma gastrin levels in the dog.,,,Pharmacology,46,4,1993.0,231-40
512,22047812.0,10.1016/j.clinthera.2011.09.023,,JOURNAL ARTICLE,"Kim JW, Kim JR, Yi S, Shin KH, Shin HS, Yoon SH, Cho JY, Kim DH, Shin SG, Jang IJ, Yu KS","Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects.",,,Clin Ther,33,11,2011.0,1819-30
3549,,,BLA:761238,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761238s000lbl.pdf,,,,2022.0,
209,9112065.0,,,JOURNAL ARTICLE,"Hoogkamer JF, Kleinbloesem CH, Nokhodian A, Ouwerkerk MJ, Lankhaar G, Ungethüm W, Kirch W",Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with impaired liver function.,,,Eur. J. Clin. Pharmacol.,51,6,1997.0,489-91
156,16399882.0,,,JOURNAL ARTICLE,"Petroski RE, Pomeroy JE, Das R, Bowman H, Yang W, Chen AP, Foster AC",Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors.,,,J. Pharmacol. Exp. Ther.,317,1,2006.0,369-77
2768,23153230.0,10.1021/jm3013147,,JOURNAL ARTICLE,"Luo G, Chen L, Conway CM, Denton R, Keavy D, Signor L, Kostich W, Lentz KA, Santone KS, Schartman R, Browning M, Tong G, Houston JG, Dubowchik GM, Macor JE","Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine",,,J Med Chem,55,23,2012.0,10644-10651
437,17234181.0,,,JOURNAL ARTICLE,"Mascia MP, Bachis E, Obili N, Maciocco E, Cocco GA, Sechi GP, Biggio G",Thiocolchicoside inhibits the activity of various subtypes of recombinant GABA(A) receptors expressed in Xenopus laevis oocytes.,,,Eur. J. Pharmacol.,558,1-3,2007.0,37-42
3704,,,NDA:217417,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217417s000lbl.pdf,,,,2023.0,
434,,,BLA:125141,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125141s219lbl.pdf,,,,2014.0,
49,18232657.0,10.1021/jm701348d,,JOURNAL ARTICLE,,Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor.,,,J Med Chem,,,2008.0,
2702,23183107.0,10.1016/j.ejphar.2012.11.023,,JOURNAL ARTICLE,"Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, Rosenberg A, Tran T, Xiao Y, Zarate CA, Wainer IW","Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors",,,Eur J Pharmacol,698,1-3,2013.0,228-34
533,12487507.0,,,JOURNAL ARTICLE,Ishide T,"Denopamine, a selective beta1-receptor agonist and a new coronary vasodilator.",,,Curr Med Res Opin,18,7,2002.0,407-13
286,,,NDA:022249,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022249Orig1s019lbl.pdf,,,,2015.0,
420,7878037.0,,,JOURNAL ARTICLE,"Double KL, Crocker AD",Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone.,,,Proc. Natl. Acad. Sci. U.S.A.,92,5,1995.0,1669-73
3690,,,BLA:761324 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761324Orig1s000MultidisciplineR.pdf,,,,2023.0,
692,21293470.0,10.1038/aps.2010.210,,JOURNAL ARTICLE,"Ji XC, Zhao WH, Cao DX, Shi QQ, Wang XL",Novel neuroprotectant chiral 3-n-butylphthalide inhibits tandem-pore-domain potassium channel TREK-1.,,,Acta Pharmacol. Sin.,32,2,2011.0,182-7
2914,,,NDA:212295,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf,,,,2020.0,
2545,,,NDA:211349,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf,,,,2018.0,
3250,,,BLA:761208,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761208Orig1s000lbledt.pdf,,,,2021.0,
638,24900196.0,10.1021/ml1000257,,JOURNAL ARTICLE,"Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, Strickley RG, Tsai LK, Stray KM, Wang Y, Rhodes GR, Desai MC",Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.,,,ACS Med Chem Lett,1,5,2010.0,209-13
42,12939461.0,,,JOURNAL ARTICLE,,Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.,,,Mol Cancer Ther,,,2003.0,
571,,,BLA:125036,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125036s0144lbl.pdf,,,,2012.0,
3255,31628188.0,10.1074/jbc.RA119.010732,,JOURNAL ARTICLE,"Niu L, Yang J, Yan W, Yu Y, Zheng Y, Ye H, Chen Q, Chen L",Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of beta-tubulin explains KXO1's low clinical toxicity,,,J Biol Chem,294,48,2019.0,18099-18108
3375,,,NDA:214907,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214907s000lbl.pdf,,,,2021.0,
385,1101049.0,,,JOURNAL ARTICLE,Youdim MB,Monoamine oxidase. Its inhibition.,,,Mod Probl Pharmacopsychiatry,10,,1975.0,65-88
590,16469866.0,,,JOURNAL ARTICLE,"Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE","Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.",,,J. Pharmacol. Exp. Ther.,317,2,2006.0,910-8
155,,,BLA:103770,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103770s5185lbl.pdf,,,,2014.0,
29,22640220.0,10.2174/187152412802430129,,JOURNAL ARTICLE,,Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system.,,,Cent Nerv Syst Agents Med Chem,,,2012.0,
648,,,EMEA/H/C/004085,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004085/WC500223723.pdf,,,,2017.0,
3672,,,NDA:217759,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217759s000lbl.pdf,,,,2023.0,
71,17179482.0,10.1093/jnci/djj498,,JOURNAL ARTICLE,,Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.,,,J Natl Cancer Inst,,,2006.0,
2763,,10.1101/2020.03.11.986836,,JOURNAL ARTICLE,"Ge Y, Tian T, Huang S, Wan F, Li J, Li S, Yang H, Hong L, Wu N, Yuan E, Cheng L, Lei Y, Shu H, Feng X, Jiang Z, Chi Y, Guo X, Cui L, Xiao L, Li Z, Yang C, Miao Z, Tang H, Chen L, Zeng H, Zhao D, Zhu F, Shen X, Zeng J",A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19,,,bioRxiv,,,2020.0,
2698,,,BLA:761079,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761079s000lbl.pdf,,,,2019.0,
128,,,EMEA/H/C/000679,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000679/WC500037902.pdf,,,,2011.0,
599,12166927.0,,,JOURNAL ARTICLE,"Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, Willson TM","6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.",,,J. Med. Chem.,45,17,2002.0,3569-72
494,15306801.0,,,JOURNAL ARTICLE,"Voets T, Droogmans G, Wissenbach U, Janssens A, Flockerzi V, Nilius B",The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels.,,,Nature,430,7001,2004.0,748-54
163,,,EMEA/H/C/003906,DRUG LABEL,,,,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003906/WC500181492.pdf,,,,2015.0,
2696,22739142.0,10.1038/clpt.2012.58,,JOURNAL ARTICLE,"Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, Ruff D, Shadoan M, Banks P, Mseeh F, Rawlins DB, Goodwin NC, Mabon R, Harrison BA, Wilson A, Sands A, Powell DR","LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial",,,Clin Pharmacol Ther,92,2,2012.0,158-69
344,18638004.0,10.1111/j.1743-6109.2008.00945.x,,JOURNAL ARTICLE,"Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG","Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction.",,,J Sex Med,5,11,2008.0,2672-80
2785,32315352.0,10.1371/journal.pone.0231877,,JOURNAL ARTICLE,"Liu PCC, Koblish H, Wu L, Bowman K, Diamond S, DiMatteo D, Zhang Y, Hansbury M, Rupar M, Wen X, Collier P, Feldman P, Klabe R, Burke KA, Soloviev M, Gardiner C, He X, Volgina A, Covington M, Ruggeri B, Wynn R, Burn TC, Scherle P, Yeleswaram S, Yao W, Huber R, Hollis G","INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models",,,PLoS One,15,4,2020.0,e0231877
2577,,,NDA:210910,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf,,,,2018.0,
3708,,,EMEA/H/C/005618,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/elfabrio-epar-product-information_en.pdf,,,,2023.0,
2782,,,NDA:213756,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf,,,,2020.0,
2933,,,NDA:213227,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213227s000lbl.pdf,,,,2020.0,
2775,,,BLA:761113,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761113s000lbl.pdf,,,,2020.0,
535,,,NDA:021396,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21396_prempro_lbl.pdf,,,,2003.0,
31,18417092.0,10.1016/j.ando.2008.02.022,,JOURNAL ARTICLE,,Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010.,,,Ann Endocrinol (Paris),,,2008.0,
204,,,BLA:125084,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125084s063lbl.pdf,,,,2015.0,
247,,,BLA:103772,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103772s5370lbl.pdf,,,,2015.0,
224,9530547.0,,,JOURNAL ARTICLE,"Gunasekara NS, Faulds D",Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.,,,Drugs,55,3,1998.0,423-35
116,1717223.0,,,JOURNAL ARTICLE,,"Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders",,,Drugs,42,2,1991.0,240-60
538,,,NDA:021825,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021825s003lbl.pdf,,,,2015.0,
3709,,,EMEA/H/C/005618 review,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/assessment-report/elfabrio-epar-public-assessment-report_en.pdf,,,,2023.0,
511,1666418.0,,,JOURNAL ARTICLE,"Kubo M, Ochiai T, Kato J, Ishida R","Pharmacological studies on TA-6366, a new ACE inhibitor: II. Effect of long-term administration from the pre-hypertensive stage on blood pressure, relative heart weight and ACE activity of various tissues in spontaneously hypertensive rats (SHRs).",,,Jpn. J. Pharmacol.,57,4,1991.0,517-26
3212,,,BLA:761174,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf,,,,2021.0,
294,,,NDA:206333,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206333Orig1s000lbl.pdf,,,,2015.0,
613,,,NDA:208341,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208341s000lbl.pdf,,,,2016.0,
472,1397053.0,,,JOURNAL ARTICLE,"Boeijinga PH, Galvan M, Baron BM, Dudley MW, Siegel BW, Slone AL",Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells.,,,Eur. J. Pharmacol.,219,1,1992.0,9-13
1903,22266222.0,10.1158/0008-5472.CAN-11-3948,,JOURNAL ARTICLE,"Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH",ARN-509: a novel antiandrogen for prostate cancer treatment.,,,Cancer Res.,72,6,2012.0,1494-503
458,24660890.0,10.1021/jm401992e,,JOURNAL ARTICLE,"Biftu T, Sinha-Roy R, Chen P, Qian X, Feng D, Kuethe JT, Scapin G, Gao YD, Yan Y, Krueger D, Bak A, Eiermann G, He J, Cox J, Hicks J, Lyons K, He H, Salituro G, Tong S, Patel S, Doss G, Petrov A, Wu J, Xu SS, Sewall C, Zhang X, Zhang B, Thornberry NA, Weber AE",Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.,,,J. Med. Chem.,57,8,2014.0,3205-12
361,,,familyId=61,ONLINE RESOURCE,,Somatostatin receptors. Accessed on 19/06/2015. IUPHAR/BPS Guide to PHARMACOLOGY,,http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=61,,,,2015.0,
3397,,,NDA:215833 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215833Orig1s000MultidisciplineR.pdf,,,,2022.0,
581,,,NDA:205109,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205109s001lbl.pdf,,,,2014.0,
3536,23623333.0,10.1016/j.crohns.2013.03.014,,JOURNAL ARTICLE,"Sugiura T, Kageyama S, Andou A, Miyazawa T, Ejima C, Nakayama A, Dohi T, Eda H","Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice",,,J Crohns Colitis,7,11,2013.0,e533-542
2541,,,NDA:210656,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf,,,,2018.0,
139,,,NDA:204447,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204447s004lbl.pdf,,,,2014.0,
524,,,NDA:008922,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/008922s016lbl.pdf,,,,2009.0,
3407,,,BLA:761235 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761235Orig1s000PharmR.pdf,,,,2022.0,
3713,,,BLA:761345 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761345Orig1s000MultidisciplineR.pdf,,,,2023.0,
3560,,,EMEA/H/C/005865 review,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/assessment-report/tecvayli-epar-public-assessment-report_en.pdf,,,,2022.0,
2753,32251768.0,10.1016/j.antiviral.2020.104787,,JOURNAL ARTICLE,"Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM",The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro,,,Antiviral Res,,,2020.0,
3206,,,NDA:211964,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211964s000lbl.pdf,,,,2021.0,
641,21443688.0,10.1111/j.1349-7006.2011.01939.x,,JOURNAL ARTICLE,"Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J, Lou L",YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.,,,Cancer Sci.,102,7,2011.0,1374-80
382,,,BLA:103293,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf,,,,2012.0,
3070,,,BLA:761172,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761172s000lbl.pdf,,,,2020.0,
373,,,020913,DRUG LABEL,,,,"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020912s021,020913s018lbl.pdf",,,,2015.0,
2,,,,ONLINE RESOURCE,Veterans Health Administration,Veterans Health Administration (VHA) National Drug File - Reference Terminology (NDF-RT),,http://www.cancer.gov/cancertopics/cancerlibrary/terminologyresources/fmt,,,,,
370,28684.0,,,JOURNAL ARTICLE,"Falliers CJ, Redding MA, Katsampes CP",Inhibition of cutaneous and mucosal allergy with phenyltoloxamine.,,,Ann Allergy,41,3,1978.0,140-4
3202,,,NDA:213498,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213498s000lbl.pdf,,,,2021.0,
3061,,,NDA:212642,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212642s000lbl.pdf,,,,2020.0,
3542,,,BLA:761310 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761310Orig1s000MultidisciplineR.pdf,,,,2022.0,
3680,37431762.0,10.1080/14712598.2023.2231344,,JOURNAL ARTICLE,Tanaka Y,Ozoralizumab: first nanobody(R) therapeutic for rheumatoid arthritis,,,Expert Opin Biol Ther,23,7,2023.0,579-587
33,22171087.0,10.1124/jpet.111.189068,,JOURNAL ARTICLE,,Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.,,,J Pharmacol Exp Ther,,,2012.0,
102,,,BLA:125557,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125557lbl.pdf,,,,2014.0,
3246,,,NDA:214662,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214662s000lbl.pdf,,,,2021.0,
2208,16135657.0,,,JOURNAL ARTICLE,"Iwanaga T, Kobayashi D, Hirayama M, Maeda T, Tamai I","Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone.",,,Drug Metab. Dispos.,33,12,2005.0,1791-5
600,,,NDA:207999,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf,,,,2016.0,
2886,10064839.0,10.1016/s0006-8993(99)01125-7,,JOURNAL ARTICLE,"Chou YC, Liao JF, Chang WY, Lin MF, Chen CF","Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan",,,Brain Res,821,2,1999.0,516-519
2716,28495802.0,10.1152/ajpgi.00044.2017,,JOURNAL ARTICLE,"Yin J, Tse CM, Cha B, Sarker R, Zhu XC, Walentinsson A, Greasley PJ, Donowitz M",A common NHE3 single-nucleotide polymorphism has normal function and sensitivity to regulatory ligands,,,Am J Physiol Gastrointest Liver Physiol,313,2,2017.0,G129-G137
384,,,NDA:207620,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207620Orig1s000lbl.pdf,,,,2015.0,
329,,,NDA:022572,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022572s003lbl.pdf,,,,2014.0,
654,,,BLA:761049,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf,,,,2017.0,
313,,,NDA:021179,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021179Orig1s030lbl.pdf,,,,2014.0,
3400,,,NDA:214998,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214998s000lbl.pdf,,,,2022.0,
479,20160034.0,10.1158/0008-5472.CAN-09-2766,,JOURNAL ARTICLE,"Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J",Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.,,,Cancer Res.,70,5,2010.0,1970-80
2548,30267321.0,10.1007/s40265-018-0987-2,,JOURNAL ARTICLE,Syed YY,Lanadelumab: First Global Approval.,,,Drugs,78,15,2018.0,1633-37
486,1354949.0,,,JOURNAL ARTICLE,"Rosenzweig P, Thebault JJ, Caplain H, Dubruc C, Bianchetti G, Fuseau E, Morselli PL","Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine.",,,Ann Allergy,69,2,1992.0,135-9
3229,,,BLA:761178 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761178Orig1s000PharmR.pdf,,,,2021.0,
18,11302816.0,10.1128/AAC.45.5.1493-1499.2001,,JOURNAL ARTICLE,,"In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs.",,,Antimicrob Agents Chemother,,,2001.0,
3275,,,NDA:215596,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215596lbl.pdf,,,,2021.0,
3192,,,NDA:214377,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf,,,,2021.0,
331,,,NDA:206940,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206940s000lbl.pdf,,,,2015.0,
3213,32134960.0,10.1371/journal.pone.0229206,,JOURNAL ARTICLE,"Brown ME, Bedinger D, Lilov A, Rathanaswami P, Vásquez M, Durand S, Wallace-Moyer I, Zhong L, Nett JH, Burnina I, Caffry I, Lynaugh H, Sinclair M, Sun T, Bukowski J, Xu Y, Abdiche YN",Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors,,,PLoS One,15,3,2020.0,e0229206
63,2851680.0,10.1254/jjp.48.349,,JOURNAL ARTICLE,,"Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor.",,,Jpn J Pharmacol,,,1988.0,
444,9368911.0,,,JOURNAL ARTICLE,"Bruhwyler J, Liégeois JF, Géczy J",Pirlindole: a selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties.,,,Pharmacol. Res.,36,1,1997.0,23-33
2940,32053994.0,10.3390/ijms21041181,,JOURNAL ARTICLE,"Petersen M, Gandhi PS, Buchardt J, Alanentalo T, Fels JJ, Johansen NL, Helding-Kvist P, Vad K, Thygesen P","Tissue distribution and receptor activation by somapacitan, a long acting growth hormone derivative",,,Int J Mol Sci,21,4,2020.0,1181
364,11502873.0,,,JOURNAL ARTICLE,"Takasaki J, Kamohara M, Saito T, Matsumoto M, Matsumoto S, Ohishi T, Soga T, Matsushime H, Furuichi K","Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor.",,,Mol. Pharmacol.,60,3,2001.0,432-9
492,15931571.0,,,JOURNAL ARTICLE,Brown WM,Taltirelin (Tanabe Seiyaku).,,,IDrugs,4,12,2001.0,1389-400
218,,,BLA:125377,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125377s055lbl.pdf,,,,2015.0,
104,22037378.0,10.1038/nbt.1990,,JOURNAL ARTICLE,,Comprehensive analysis of kinase inhibitor selectivity,,,Nat Biotechnol,29,11,2011.0,
625,,,BLA:761046,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761046s000lbl.pdf,,,,2016.0,
549,12749884.0,,,JOURNAL ARTICLE,"Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, Mohr M",Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.,,,Bioorg. Med. Chem. Lett.,13,11,2003.0,1857-9
400,,,NDA:022037,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022037s011lbl.pdf,,,,2015.0,
594,9713295.0,,,JOURNAL ARTICLE,"Denis L, Debruyne F, De Porre P, Bruynseels J",Early clinical experience with liarozole (Liazal) in patients with progressive prostate cancer.,,,Eur. J. Cancer,34,4,1998.0,469-75
508,,,NDA:207988,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf,,,,2015.0,
3261,,,000233074,DRUG LABEL,,,,https://www.pmda.go.jp/files/000233074.pdf,,,,2021.0,
2529,24211136.0,10.1016/j.chembiol.2013.09.017,,JOURNAL ARTICLE,"Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, Macdougall JR, Ren P, Liu Y, Li LS, Jessen KA, Fritz CC, Dunbar JL, Porter JR, Rommel C, Palombella VJ, Changelian PS, Kutok JL",PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.,,,Chem. Biol.,20,11,2013.0,1364-74
2934,29668724.0,10.1371/journal.pone.0195802,,JOURNAL ARTICLE,"Rylova SN, Stoykow C, Del Pozzo L, Abiraj K, Tamma ML, Kiefer Y, Fani M, Maecke HR",The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft mod,,,PLoS One,13,4,2018.0,e0195802
284,3924048.0,,,JOURNAL ARTICLE,"Bitonti AJ, Bacchi CJ, McCann PP, Sjoerdsma A",Catalytic irreversible inhibition of Trypanosoma brucei brucei ornithine decarboxylase by substrate and product analogs and their effects on murine trypanosomiasis.,,,Biochem. Pharmacol.,34,10,1985.0,1773-7
2710,27003761.0,10.1021/acs.jmedchem.6b00064,,JOURNAL ARTICLE,"Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P","Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor",,,J Med Chem,59,7,2016.0,3392-3408
241,18306243.0,10.1002/ana.21315,,JOURNAL ARTICLE,"LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM","Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces ""off"" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).",,,Ann. Neurol.,63,3,2008.0,295-302
3669,,,NDA:216718,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216718Orig1s000lbl.pdf,,,,2023.0,
3405,,,BLA:761234,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdf,,,,2022.0,
215,,,BLA:125147,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125147s200lbl.pdf,,,,2015.0,
3,,,,ONLINE RESOURCE,Wolters Kluwer Health,Lexicomp Online,,http://www.lexi.com,,,,,
478,,,NDA:208462,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf,,,,2015.0,
2522,,,NDA:211192,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf,,,,2018.0,
3210,,,NDA:214154,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214154s000lbl.pdf,,,,2021.0,
402,,,BLA:103950,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103950s5150lbl.pdf,,,,2013.0,
3705,,,NDA:217417 review,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217417Orig1s000IntegratedR.pdf,,,,2023.0,
311,,,NDA:021029,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s028lbl.pdf,,,,2015.0,
295,,,NDA:022575,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022575s012lbl.pdf,,,,2013.0,
2727,,,NDA:212028,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf,,,,2019.0,
2692,,,BLA:761105,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf,,,,2019.0,
37,17154430.0,10.1002/cmdc.200600221,,JOURNAL ARTICLE,,Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.,,,ChemMedChem,,,2007.0,
510,10487332.0,,,JOURNAL ARTICLE,Timmermans PB,Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics.,,,Hypertens. Res.,22,2,1999.0,147-53
2311,16946104.0,10.1124/jpet.106.109058,,JOURNAL ARTICLE,"Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E,  Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES.","R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.",,https://doi.org/10.1124/jpet.106.109058,J Pharmacol Exp Ther.,319,3,2006.0,998–1008
553,8821512.0,,,JOURNAL ARTICLE,"Guarneri L, Angelico P, Ibba M, Poggesi E, Taddei C, Leonardi A, Testa R","Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.",,,Arzneimittelforschung,46,1,1996.0,15-24
2551,30465134.0,10.1007/s40265-018-1016-1,,JOURNAL ARTICLE,Duggan S,Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval.,,,Drugs,78,18,2018.0,1925-29
409,22037049.0,10.1016/j.bmc.2011.10.007,,JOURNAL ARTICLE,"Lewin AH, Miller GM, Gilmour B",Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.,,,Bioorg. Med. Chem.,19,23,2011.0,7044-8
191,,,NDA:202057,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202057s009lbl.pdf,,,,2013.0,
679,,,BLA:761061,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf,,,,2017.0,
582,,,NDA:020057,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020057s034lbl.pdf,,,,2006.0,
3226,,,NDA:214900,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214900s000lbl.pdf,,,,2021.0,
2008,12240910.0,,,JOURNAL ARTICLE,"Broglio F, Boutignon F, Benso A, Gottero C, Prodam F, Arvat E, Ghè C, Catapano F, Torsello A, Locatelli V, Muccioli G, Boeglin D, Guerlavais V, Fehrentz JA, Martinez J, Ghigo E, Deghenghi R",EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man.,,,J. Endocrinol. Invest.,25,8,2002.0,RC26-8
2417,,,NDA:210496,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf,,,,2018.0,
60,21651903.0,10.1016/j.ejphar.2011.05.054,,JOURNAL ARTICLE,,Pregabalin is a potent and selective ligand for alpha(2)delta-1 and alpha(2)delta-2 calcium channel subunits.,,,Eur J Pharmacol,,,2011.0,
3047,24006460.0,10.4049/jimmunol.1201348,,JOURNAL ARTICLE,"Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, Lepescheux L, Christophe T, Conrath K, Vandeghinste N, Vayssiere B, De Vos S, Fletcher S, Brys R, van't Klooster G, Feyen JH, Menet C","Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases",,,J Immunol,191,7,2013.0,3568-3577
223,,,NDA:206162,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf,,,,2014.0,
350,9792651.0,,,JOURNAL ARTICLE,"Cotte N, Balestre MN, Phalipou S, Hibert M, Manning M, Barberis C, Mouillac B",Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor.,,,J. Biol. Chem.,273,45,1998.0,29462-8
135,17071817.0,,,JOURNAL ARTICLE,"Su S, Ohno Y, Lossin C, Hibino H, Inanobe A, Kurachi Y","Inhibition of astroglial inwardly rectifying Kir4.1 channels by a tricyclic antidepressant, nortriptyline.",,,J. Pharmacol. Exp. Ther.,320,2,2007.0,573-80
684,28193778.0,10.1158/2159-8290.CD-16-1034,,JOURNAL ARTICLE,"Yen K, Travins J, Wang F, David MD, Artin E, Straley K, Padyana A, Gross S, DeLaBarre B, Tobin E, Chen Y, Nagaraja R, Choe S, Jin L, Konteatis Z, Cianchetta G, Saunders JO, Salituro FG, Quivoron C, Opolon P, Bawa O, Saada V, Paci A, Broutin S, Bernard OA, de Botton S, Marteyn BS, Pilichowska M, Xu Y, Fang C, Jiang F, Wei W, Jin S, Silverman L, Liu W, Yang H, Dang L, Dorsch M, Penard-Lacronique V, Biller SA, Su SM","AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.",,,Cancer Discov,7,5,2017.0,478-493
143,10742287.0,,,JOURNAL ARTICLE,"Gopalakrishnan M, Molinari EJ, Shieh CC, Monteggia LM, Roch JM, Whiteaker KL, Scott VE, Sullivan JP, Brioni JD",Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells.,,,Br. J. Pharmacol.,129,7,2000.0,1323-32
426,20209107.0,10.1371/journal.pone.0009430,,JOURNAL ARTICLE,"Humbert M, Castéran N, Letard S, Hanssens K, Iovanna J, Finetti P, Bertucci F, Bader T, Mansfield CD, Moussy A, Hermine O, Dubreuil P",Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.,,,PLoS ONE,5,3,2010.0,e9430
604,,,BLA:103951,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103951s5363lbl.pdf,,,,2015.0,
664,26562265.0,10.1210/en.2015-1726,,JOURNAL ARTICLE,"Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ",Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.,,,Endocrinology,157,1,2016.0,141-9
2559,,,BLA:761108,DRUG LABEL,,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761108s000lbl.pdf,,,,2018.0,
343,14681344.0,,,JOURNAL ARTICLE,"Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS","Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers.",,,J Clin Pharmacol,44,1,2004.0,73-82
646,12152654.0,,,JOURNAL ARTICLE,"Gils A, Stassen JM, Nar H, Kley JT, Wienen W, Ries UJ, Declerck PJ",Characterization and comparative evaluation of a novel PAI-1 inhibitor.,,,Thromb. Haemost.,88,1,2002.0,137-43
2744,,,NDA:211672,DRUG LABEL,,,,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf",,,,2019.0,
178,23913691.0,10.1074/jbc.M113.485979,,JOURNAL ARTICLE,"Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Réville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL","Kinetics of avibactam inhibition against Class A, C, and D β-lactamases.",,,J. Biol. Chem.,288,39,2013.0,27960-71
3043,,,EMEA/H/C/004854,DRUG LABEL,,,,https://www.ema.europa.eu/en/documents/product-information/hepcludex-epar-product-information_en.pdf,,,,2020.0,
1300,16982756.0,,,JOURNAL ARTICLE,"Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isae T","KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.",,,Cancer Res.,66,18,2006.0,9134-42
894,21396362.0,10.1016/j.exer.2011.03.001,,JOURNAL ARTICLE,"Krauss AH, Impagnatiello F, Toris CB, Gale DC, Prasanna G, Borghi V, Chiroli V, Chong WK, Carreiro ST, Ongini E","Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.",,,Exp. Eye Res.,93,3,2011.0,250-5
251,,,NDA:021756,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021756s018lbl.pdf,,,,2011.0,
588,,,BLA:103471,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103471s5188lbl.pdf,,,,2015.0,
205,24936658.0,10.1371/journal.pone.0099440,,JOURNAL ARTICLE,"Benod C, Villagomez R, Filgueira CS, Hwang PK, Leonard PG, Poncet-Montange G, Rajagopalan S, Fletterick RJ, Gustafsson JÅ, Webb P","The human orphan nuclear receptor tailless (TLX, NR2E1) is druggable.",,,PLoS ONE,9,6,2014.0,e99440
528,15740719.0,,,JOURNAL ARTICLE,"Gimpl G, Postina R, Fahrenholz F, Reinheimer T",Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.,,,Eur. J. Pharmacol.,510,1-2,2005.0,9-16
268,8950316.0,,,JOURNAL ARTICLE,"Uchiyama-Tsuyuki Y, Saitoh M, Muramatsu M",Identification and characterization of the 5-HT4 receptor in the intestinal tract and striatum of the guinea pig.,,,Life Sci.,59,25-26,1996.0,2129-37
166,12191614.0,,,JOURNAL ARTICLE,"Sasaki Y, Suzuki M, Hidaka H",The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway.,,,Pharmacol. Ther.,93,2-3,2002.0,225-32
278,,,NDA:203568,DRUG LABEL,,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203568s004lbl.pdf,,,,2015.0,
3274,,,NDA:215358 review,DRUG LABEL,,,,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215358Orig1s000,Orig2s000MultidisciplineR.pdf",,,,2021.0,
449,17005916.0,,,JOURNAL ARTICLE,"Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau A, Gbahou F, Arrang JM, Ganellin CR, Stark H, Schunack W, Schwartz JC","BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology.",,,J. Pharmacol. Exp. Ther.,320,1,2007.0,365-75
2540,29736245.0,10.1002/prp2.400,,JOURNAL ARTICLE,"Hegde SS, Pulido-Rios MT, Luttmann MA, Foley JJ, Hunsberger GE, Steinfeld T, Lee T, Ji Y, Mammen MM, Jasper JR","Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues.",,,Pharmacol. Res. Perspect.,6,3,2018.0,e00400
